

UNITED STATES DISTRICT COURT
FOR THE
DISTRICT OF MASSACHUSETTS

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK
VARIABLE LIFE INSURANCE
COMPANY, and MANULIFE
INSURANCE COMPANY (f/k/a
INVESTORS PARTNER INSURANCE
COMPANY,

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendant.

CIVIL ACTION NO. 05-11150-DPW

AFFIDAVIT OF KENNETH STILES

I, Kenneth Stiles, do hereby declare and say:

1. My name is Kenneth Stiles. I am over 18 years of age and suffer from no condition or disability that would impair my ability to give sworn testimony. This affidavit is based upon my own personal knowledge.

Educational and Professional Background

2. I am currently employed by Abbott Laboratories ("Abbott") as Assistant Controller for Global Pharmaceutical Research and Development ("GPRD") Financial Business Solutions. I was appointed to that position approximately two years ago. In my current position, I am responsible for developing improvements to GPRD's financial systems applications (*i.e.*, the computer software that is used for financial

management) and financial processes (*i.e.*, processes for approval of expenditures). I serve as a bridge between users of the financial data within Abbott, such as the financial analysts who support the research and development (“R&D”) personnel, and the information technology personnel. I report to Brian Durkin, the Senior Director of Finance and Operations.

3. I received my Bachelor of Science degree in Transportation Management from Indiana University in 1978. I received my Masters in Business Administration in Finance from DePaul University in 1982. I received a Certificate of Management Accounting in 1985.

4. I joined Abbott after graduation from college in 1978. For the first two years, I held inventory accounting positions. Starting in 1980, I held a variety of positions at Abbott in which I was responsible for financial analysis, planning, and/or accounting. The positions that I held at Abbott between 1980 and 2001 included Senior Financial Analyst in Corporate Materials Management, Senior Financial Analyst for the Pharmaceuticals Products Division (“PPD”), Senior Cost Analyst for the PPD, Supervisor of Puerto Rico Financial Operations, Manager Financial Planning and Analysis for Abbott Diagnostics Division (“ADD”), Commercial Controller for ADD United States and Canada Operations, and Controller for MediSense Operations in ADD.

5. From May 2001 to 2005, I served as Assistant Division Controller in GPRD. I reported to the GPRD Controller. When I first started, Tom Lyons was the GRPD Controller. Subsequently, during my tenure in that position Kraig Moffatt was GRPD Controller. Several individuals reported to me and worked under my direction,

including Tom Woidat and Rich Pinto. As Assistant Division Controller, I was responsible for financial planning, reporting, and controls. More specifically, with respect to planning, I worked with operations personnel in R&D to develop budgets, compared actual with budgeted spending, and highlighted variances to senior management. With respect to reporting, I compiled monthly consolidated expenditure reports for management. With respect to financial controls, I was responsible, along with others in my department, for ensuring that the financial practices complied with generally accepted accounting procedures (“GAAP”), corporate policy, and applicable laws and regulations.

6. In managing R&D operations, Abbott monitors spending by “project.” If a compound has only one indication, project refers to the overall development of that particular compound. If the compound has more than one indication (*e.g.*, a tablet form and I.V. form), “project” refers to each indication.

7. During my tenure as Assistant Division Controller, Abbott recorded its actual spending in the Financial Management System (“FMS”). I, along with others in my department, generated expense reports on a “functional” or “departmental” level from this system. The functional reports reflected spending organized by function or service area, and were the basis for submissions to Abbott Finance headquarters. These submissions were consolidated with results from other Abbott operating units and ultimately used for external reporting, such as reports filed with the Securities Exchange Commission.

8. The FMS system was not (and is not) the official system of record for project expense data. For internal management purposes, GPRD used a software

application called the Comprehensive Project Accounting System, commonly referred to as COMPASS, to record and produce reports reflecting actual expenditures by project. Under GRPD's standard procedures, manpower rates were calculated for each service area by dividing the projected total year level of spending for a service area by the number of manpower hours expected to be available that year for the service area. Overhead was allocated to each service area and built into the manpower rates. R&D personnel completed time sheets reflecting time spent on each project and those time records were entered into COMPASS. In the COMPASS system, the project expense rates were multiplied by the number of hours recorded on the project, and the resulting expense level was added to non-personnel expenditures on the project to determine the estimated actual expenditures on each project. My staff and I generated project expense reports from the COMPASS system, which reflected our reasonable estimate of actual expenditures by project. GPRD Finance routinely produced the project expense reports in the ordinary course of business in support of operating management's monitoring of actual expenditures by project.

9. Attached hereto as D's Exhibit 786 are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures during 2001 on research and development of the Program Compounds that are included in the Research Funding Agreement between John Hancock and Abbott, *i.e.*, franesytransferase ("FTI"), quinolone (ABT-492), TSP Peptide (ABT-510), the MMPI program (ABT-770/ABT-518), CCM (ABT-594), endothelin (ABT-627), erectile dysfunction and dopamine (the "ED" program), Eisai (ABT-751), and ketolide (ABT-773).

10. Attached hereto as D's Exhibit FC are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2002 on research and development of the Program Compounds, with the exception of ABT-594.

11. Attached hereto as D's Exhibit FD is a true and correct copy of a project expense report reflecting Abbott's actual monthly and annual expenditures in 2002 on research and development of ABT-594.

12. Attached hereto as D's Exhibit FE are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2003 on research and development of the Program Compounds.

13. Attached hereto as D's Exhibit FF are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2004 on research and development of the Program Compounds.

14. Attached hereto as D's Exhibit FG are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2005 on research and development of the Program Compounds.

15. In the course of the Research Funding Agreement, Abbott provided Annual Research Plans ("ARPs") to Hancock, which reported, among other things, expenditures to date on the compounds. In Fall 2007, in response to what I understood to be a request by John Hancock for information regarding Abbott's actual expenditures by month during 2001, I assisted Abbott counsel with the preparation of an amended interrogatory response that would provide that information. In the course of preparing that interrogatory response, I reviewed and analyzed Abbott's project expense reports. Based on that review and analysis, I determined that the ARPs, and

Abbott's original interrogatory response that I verified on June 27, 2006, inadvertently underreported Abbott's actual expenditures during the 2001 to 2005 period on certain Program Compounds. Based on my analysis, it appears that primary omissions were expenditures incurred by Abbott between January 2001 to July 2001 on development of ABT-100 (FTI) and ABT-724 (ED/Dopamine), certain milestone payments to Wakunaga Pharmaceutical for the development of ABT-492 (quinolone), and expenditures in 2002 incurred at Abbott's Ludwigshafen facility in Germany on development of several Program Compounds.

16. It appears that the ARP and original interrogatory responses also may also have understated expenditures on ABT-773 in 2001 and 2002. A project expense report that I analyzed, which listed expenditures by timekeepers, rather than by month, reflects a higher level of expenditures by Abbott on ABT-773 in 2001 and 2002 than is reflected in the project expense reports that list expenditures by month. Based on my analysis, it appeared that the complete expenditures on the ABT-773 Japan program were not fully reflected in the project expense report listing expenditures by month. For the sake of conservatism, however, I relied on the GPRD reports listing monthly expenditures, rather than the timekeeper report, in reporting the expenditure figures for ABT-773 in Abbott's Amended Responses and Objections to Plaintiffs' Second Set of Interrogatories.

17. Attached hereto as D's Exhibit FO is a true and correct copy of Abbott's Amended Responses and Objections to Plaintiffs' Second Set of Interrogatories, which, in the amended response to Interrogatory Number 15, set forth Abbott's annual expenditures on research and development of the Program Compounds from 2001 to

2005, and which attach the project expense reports showing monthly expenditures on the Program Compounds in 2001. This concludes my testimony.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed on February 17, 2008 at Vernon Hills, Il.


Kenneth Stiles

PAGE 9-11
20-Jan-02

PHARMACEUTICAL R&D
SCHEDULED FUTURE PROJECT FUNDING REPORT
FRI #2 (ABT-102)

	MONTHLY RESULTS												YEAR END			
	1	2	3	4	5	6	7	8	9	10	11	12	YTD	Approved	YTD	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Actual	Approved	Actual	Var
Drug Safety	12	23	49	53	57	17			(16)	27			211	202	211	(9)
Drug Safety	142	183	159	106	107	50	41		(51)				764	697	764	(67)
Metabolism	12	43	31	36	13	2		5	(2)				140	811	140	671
Toxicology/Pathology		44	136	206	121	39	23	22	(31)	2	4	3	569	881	569	312
Comparative Medicine		6	71	32	16	2		(1)					126	(514)	126	(640)
Medical Affairs																
Outcomes Res/Admin			1	1	1	1			1	1	1		7	5	7	(2)
Medical Services																
Phase-1 Center	1	11				(12)			21				21	32	21	11
Clinical				4		16			(20)					6		6
ACR/RT - Direct																
Development Operations																
Data Management	1			5	21	1			(1)				1	59	1	58
Biostatistics	7					10				2	2	1	33	(9)	33	(41)
International Manpower																
Grants																
International Directors	13	11	26	15	9	14	10	10	(3)	11	11	4	131	92	131	(39)
Venture Management	20	68	72	65	111	9	2	2	(6)		1		344	334	344	(10)
PARC					1	1	1	1		(4)						
Regulatory/IRIC			1	8	13	2	2	7	3	5	2	1	45	165	45	120
Research QA																
Strategic Scientific Operation	2	2	(4)		7	11		8	1	(4)			25	98	25	73
Investigational Drug QA																
SPD																
License Paymt/Royalty					11	3	(13)		(10)	7		4	2		2	(2)
Other																
Judgment																
Total Global	202	400	553	566	473	139	81	55	(114)	47	21	14	2,437	2,882	2,437	445

COMMENTS

CONFIDENTIAL
ABBT0578016

COMMENTS

CONFIDENTIAL
ABBT0578017

COMMENTS

20-JUN-08

PAGE 8-6

GLOBAL RESEARCH & DEVELOPMENT EXPENSE REPORT
EndoHein (ABT-627)

	MONTHLY RESULTS												YTD			YEAR-END		
	1	2	3	4	5	6	7	8	9	10	11	12	Total	Approved USD	Var	Proj Year-End	Approved UPDATE	Va
Jan																		
Feb																		
March																		
April																		
May																		
June																		
July																		
Aug																		
Sept																		
Oct																		
Nov																		
Dec																		
Discovery	17	9	29	12	20	26	11	62	73	69	72	118	518	166	(353)	518	166	(353)
Process Chemistry	26	74	102	68	140	102	206	141	91	89	85	826	1,950	2,200	250	1,950	2,200	250
Drug Safety	15	14	39	59	61	50	107	142	106	119	228	96	1,042	968	(74)	1,042	968	(74)
Metabolism	21	1	18	14	17	9	11	10	...	30	131	435	(74)	131	435	(74)
Toxicology/Pathology	6	2	(6)	9	18	31	52	21	31	52	21
Comparative Medicine
Medical Affairs	88	206	220	221	200	179	17	43	285	17	17	16	1,506	200	(1,307)	1,506	200	(1,307)
Outcomes Res/Admin	35	35	35	35	35	34	35	35	34	35	35	35	418	404	(14)	418	404	(14)
Medical Services
Phase-1 Center	11	51	1	...	(62)	1	148	...	86	34	45	24	339	458	119	339	458	119
Clinical	43	15	124	232	(73)	242	29	541	86	39	1,278	1,424	146	1,278	1,424	146
ACPRU - Direct
Development Operations	54	51	138	70	110	76	88	144	163	151	268	150	1,463	2,840	1,377	1,463	2,840	1,377
Data Management	62	117	164	115	141	127	114	166	127	179	177	88	1,577	1,335	(242)	1,577	1,335	(242)
Biostatistics	8	8	9	8	100	100	...	100	100	...
International Manpower	1,964	1,964	1,965	1,965	1,964	1,965	1,964	2,189	2,599	1,964	2,174	1,732	24,409	27,344	2,935	24,409	27,344	2,935
Grants
International Directors	492	400	...	549	344	549	610	672	765	688	720	276	6,065	6,021	(44)	6,065	6,021	(44)
Venture Management	268	444	614	908	753	756	491	1,588	(325)	453	679	772	7,401	5,952	(1,449)	7,401	5,952	(1,449)
PARC
Regulatory/RIC
Research QA	4	21	62	45	76	16	7	15	19	9	41	289	645	659	14	645	659	14
Strategic Scientific Operation	5	7	8	57	38	23	46	36	...	2	...	3	52	429	377	52	429	377
Investigational Drug QA	7	28	(35)	6	...	2	11	26	63	300	132	164	815	370	(445)	815	370	(445)
SPD
License Pymt/Royalty	33	7	(4)	(1)	3	7	309	302	7	309	302
Other	(1)	2	(1)
Judgment	247	901	...	665	277	2,090	...	(2,090)	2,090	...	(2,090)
LU
Total Global	3,048	3,421	3,406	4,205	4,027	4,181	3,819	5,784	5,036	4,506	5,441	4,963	51,837	51,667	(170)	51,837	51,667	(170)

COMMENTS

CONFIDENTIAL
ABBT0578019

COMMENTS

CONFIDENTIAL
ABBT0578020

20-JUN-07

PAGE 8-9

PHARMACIA INC. PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
Anti-Malaric (ABT-751)

	MONTHLY RESULTS												YEAR-END	
	1	2	3	4	5	6	7	8	9	10	11	12	YTD Approved YTD	YTD Approved YTD
Discovery	1	3	16	8	7	4	23	33	17	20	24	133	289	216
Process Chemistry	134	198	116	82	91	67	59	91	130	299	276	90	1,633	1,108
Drug Safety														
Metabolism	15	21	7	19	36	32	10	9	3	14	22	18	206	1,419
Toxicology/Pathology	1	...	1	...	5	3	2	2	3	6	13	3	38	1,056
Comparative Medicine	1	26	30	...	9	...	70	205
Medical Affairs														
Outcomes Res/Admin	5	5	5	5	5	5	4	5	5	5	5	5	59	49
Medical Services														
Phase-I Center	1	2	3	...	3	2	7	1	19	145
Clinical							(5)							
ACPRU - Direct														
Development Operations	16	12	34	17	22	24	26	15	11	10	12	15	214	604
Data Management	3	5	11	3	1	12	17	3	9	4	4	3	75	370
Biostatistics														
International Manpower	205	205	205	499	324	211	211	212	359	(155)	361	188	2,825	4,952
Grants														
International Directors	117	95	234	131	82	130	149	164	188	168	176	68	1,702	1,473
Venture Management	75	125	212	164	203	129	179	191	210	229	218	173	2,108	2,965
PARO							2		(3)					
Regulatory/IRIC	1	8	38	27	15	17	20	9	30	36	16	15	232	351
Research QA	...	2	2	2	2	2	1	2	2	2	1	1	19	0
Strategic Scientific Operation	5	(2)	(3)	...	8	11	...	13	11	7	9	11	78	150
Investigational Drug QA														
SPD														
License Pymt/Royalty							6		(2)	(4)	3	(1)		
Other														
Judgment								117	11		2	2	132	
LU														
Total Global	579	679	878	966	805	648	712	892	1,015	643	1,159	725	9,700	15,062
													9,700	15,062
													5,362	5,362

COMMENTS

CONFIDENTIAL
ABBT0578021

PAGE 8-15
20 JAN 02

PHARMACEUTICAL PRODUCTS R&D
GLOBAL OPERATIONS EXPENSE REPORT
Ketide (ABT-773)

	MONTHLY RESULTS												YEAR-TO-DATE		Yr
	1	2	3	4	5	6	7	8	9	10	11	12	YTD	Approved	Yr
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Actual	Approved	Yr
Discovery	141	203	166	133	161	101	1	2	1	1	3	1	914	1,213	299
Process Chemistry	501	536	373	227	182	50	38	31	21	(1)	1	110	2,089	2,127	38
Drug Safety	47	74	62	49	34	8	2	1	2	1	4	20	304	863	559
Metabolism	6	6	8	2	4	42	4	3	2	1	5	6	88	419	331
Toxicology/Pathology	30	26	44	17	23	14	10	13	12	7	14	(140)	70	(25)	(95)
Comparative Medicine	12	12	12	13	12	13	12	13	22	13	12	(125)	21	8	(13)
Medical Affairs	57	56	56	57	57	56	57	57	56	57	56	(454)	168	168	(1)
Outcomes Res/Admin	25	45	3	(64)	5	3	105	12	40	13	8	17	200	351	151
Medical Services	38	66	56	17	(80)	12	10	3	11	6	139	98	(41)
Phase-I Center	99	149	188	114	163	98	97	90	59	82	57	35	1,231	1,232	1
Clinical	56	45	59	65	91	70	65	98	51	53	71	61	785	629	(156)
ACPRU - Direct	75	13	13	(7)	(6)	(7)	(6)	75	75	..
Development Operations	1,847	1,831	(3,512)	86	..	1	..	305	1,103	(1,959)	(296)	1,482	1,778
Data Management	323	323	323	323	323	323	323	323	323	323	222	226	3,678	5,054	1,376
Biostatistics	231	402	360	484	272	129	101	612	(434)	47	69	35	2,308	2,422	114
International Manpower	28	61	67	22	74	23	33	14	2	10	22	(51)	305	305	(0)
Grants	6	3	2	3	4	3	3	3	..	1	3	4	35	493	458
International Directors	10	23	(33)	25	9	22	3	6	27	237	43	35	409	132	(278)
Venture Management
PARO
Regulatory/IRIC
Research QA
Strategic Scientific Operation
Investigational Drug QA
SPD
License Pmt/Royalty
Other
Judgment
LU
Total Global	3,419	3,815	(1,804)	1,835	1,578	1,011	636	2,356	1,514	665	865	(2,233)	13,856	17,044	3,187

COMMENTS

CONFIDENTIAL
ABBT0578022

R0025

Page 1

Comprehensive Project Accounting System
DINGII -- Project Detail - December, 2002

Project Code	Project	Ben Code	Class Code	Tax Code	Div Code	Dept Code	Cost/Emp Code	Cost/Employee Description	Current Hours	Current Cost	YTD Hours	YTD Cost
1-3010	ABT-594 (CCM) Base Program	G0	2	Q	20	0421	E91700	MISC EXP	0.00	0.00	0.00	9,727.70
						0421	618740	ASHLEY, JUDITH	0.00	0.00	11.00	1,202.30
						0421	248620	BAUER, JOSEPH	0.00	0.00	5.00	546.50
						0421	618750	BIXLER, VICKI	0.00	0.00	12.75	1,393.58
						0421	264760	BURNES, MARION	7.00	765.10	11.00	1,202.30
						0421	618760	COOKE, MARCIA	0.00	0.00	3.00	327.90
						0421	C092648	CRAVEN, JOLENE	0.00	0.00	20.00	2,186.00
						0421	C093805	DROBNICK, MARK	0.00	0.00	2.00	218.60
						0421	C092077	FRANKLIN, A	0.00	0.00	19.00	2,076.70
						0421	152180	FRYBARGER, DEBBIE	0.00	218.60	71.00	7,760.30
						0421	144440	GATTAN, MARIA A	12.00	1,311.60	22.00	2,404.60
						0421	549500	GRIFFIN, BETTIE	0.00	0.00	63.00	6,885.90
						0421	264630	JOINSTON, LYNN	0.00	0.00	9.00	983.70
						0421	425360	LUCERO, STEVE	0.00	0.00	136.00	14,864.80
						0421	C093585	MANHATY, LEAH	0.00	0.00	19.00	2,076.70
						0421	C093589	MASON, KOSHONYA	0.00	0.00	24.00	2,623.20
						0421	264740	MELLENDEZ, A	0.00	0.00	48.00	5,246.40
						0421	040490	NELSON, TIELMA	0.00	0.00	5.00	546.50
						0421	194320	PETROVIC, ZLATA	0.00	0.00	16.00	1,748.80
						0421	268790	PRITCHETT, SHIRLEY	0.00	0.00	3.00	327.90
						0421	485620	QUIROZ, T	0.00	0.00	11.00	1,202.30
						0421	319900	TURK, PATRICIA M	0.00	0.00	10.00	1,093.00
						0421	234500	WRIGHT, JOSEPH	4.00	437.20	43.00	4,699.90
						0421	397280	YATES, DONNA	0.00	0.00	5.00	546.50
								Department 0421 Total:	25.00	2,732.50	568.75	71,892.08
						0491	E91700	MISC EXP	0.00	0.00	0.00	1,416.60
						0491	394180	ROSS, DAVID	0.00	0.00	14.00	1,481.24
								Department 0491 Total:	0.00	0.00	14.00	3,397.84
								Division 20 Total:	25.00	2,732.50	582.75	75,291.92
					44	R424	104820	BARNES, DIANE	0.00	0.00	30.00	4,866.60
						R424	549450	GRIMM, DAVID	0.00	0.00	8.00	1,297.76
						R424	329150	KATZ, DAVID	0.00	0.00	1.00	162.22
								Department R424 Total:	0.00	0.00	39.00	6,326.58
					46	R468	E97760	CNSLT CNTR	0.00	0.00	0.00	642.00
						R468	664430	ABBOTT, JENNIFER	0.00	0.00	1.00	159.41
						R468	654700	HOFFER, CHRISTOPHER	2.00	318.82	2.00	318.82
						R468	654450	RIZZO, RODOLFO	4.00	637.64	4.00	637.64
								Department R468 Total:	6.00	956.46	7.00	1,757.87
						R469	359240	CAMARATO, AMY	0.00	0.00	24.00	3,825.84
						R469	236670	MORFITT, DAVID	0.00	0.00	2.00	318.82
								Department R469 Total:	0.00	0.00	26.00	4,144.66
						R46W	498900	CHAMBERS, SUSAN	0.00	0.00	2.00	275.02
						R46W	C093964	TAKALA, R	0.00	0.00	6.00	825.07
								Department R46W Total:	0.00	0.00	8.00	1,100.09
						R47D	381180	DAVILA-SWEDLUND, DONNA	0.00	0.00	14.00	2,231.74
								Department R47D Total:	0.00	0.00	14.00	2,231.74
					47	R4P1	083940	BROWN, CYNTHIA	0.00	0.00	30.00	3,895.20
						R4P1	137140	GOULD, ROSE-MARIE	0.00	0.00	32.00	4,154.88
						R4P1	392780	SCHINDELDECKER, TERRY	0.00	0.00	5.00	649.20
						R4P1	330620	SONI, BINITA	0.00	0.00	30.00	3,895.20

CONFIDENTIAL
ABBT0578023

Page 2

COMprehensive Project Accounting SysTem
DINGII -- Project Detail -- December, 2002

R0025

Project Code	Project	Ben Code	Class Code	Tax Code	Div Code	Dept Code	Cost/Emp Code	Cost/Employees Description	Current Hours	Current Cost	YTD Hours	YTD Cost
13010	ABT-594 (CCM) Basic Program	G0	2	Q		R4P1	387980	VILLALOBOS, BENITA	0.00	0.00	35.00	4,544.40
						R4P7	157000	Department R4P1 Total:	0.00	0.00	132.00	17,138.85
						R4P7	532860	HILYER, ERSKINE	0.00	0.00	20.00	2,596.80
						R4P7	137480	JAYARAMAN, SIYAMALA	0.00	0.00	8.00	1,038.72
						R4P7		MYERS, THOMAS	0.00	0.00	208.50	27,071.64
						R4R2	255000	Department R4P7 Total:	0.00	0.00	236.50	30,707.16
						R4R2	409870	ALFANO, NICK	0.00	0.00	5.00	625.00
						R4R2		KRUMDICK, ORVILLE	0.00	0.00	6.00	750.00
								Department R4R2 Total:	0.00	0.00	11.00	1,375.00
								Division 47 Total:	0.00	0.00	379.50	49,221.04
					52	R431	473990	HAN, LIXIN	0.00	0.00	4.00	423.28
						R431	440440	LIN, C	0.00	0.00	4.00	423.28
						R433	318060	Department R431 Total:	0.00	0.00	8.00	846.56
						R433	C093816	LANDWER, KATHERINE	0.00	0.00	0.50	47.87
						R433	C093949	LEWIS, SHAWN	0.00	0.00	16.50	1,579.72
						R433	218250	NEIMAN, MITCHELL	0.00	0.00	3.50	335.09
						R433		PROUTY, GLENN	0.00	0.00	0.50	47.87
								Department R433 Total:	0.00	0.00	21.00	2,010.55
						R436	619830	CHUI, WENZI	0.00	0.00	82.50	8,730.15
						R436	013080	DFAITON, ROGER	0.00	0.00	4.00	423.28
						R436	330690	THOMAS, JAMES	0.00	423.28	9.00	952.38
								Department R436 Total:	4.00	423.28	95.50	10,105.81
								Division 52 Total:	4.00	423.28	124.50	12,962.92
					53	R44F	598960	FRANZ, LISA	0.00	0.00	28.00	3,966.48
						R44F	095570	JENSEN, MICHELLE	0.00	0.00	6.00	849.96
						R44F	319650	SNALL, MARIA	0.00	0.00	7.00	991.62
								Department R44F Total:	0.00	0.00	41.00	5,808.06
						R44N	028870	NGUYEN, HAI	0.00	0.00	1.00	120.82
						R4QE	176650	GUICH, D	0.00	0.00	13.00	1,841.58
								Division 53 Total:	0.00	0.00	55.00	7,770.46
								INTL SUPPORT	0.00	-4,166.66	0.00	0.00
					56	R421	191830	DOMESTIC GRANTS	0.00	0.00	0.00	-627,232.30
					59	R49G	G99910	SHULTIS, BONNIE	0.00	0.00	7.00	522.41
					62	R461	010300	BURT, DAVID	0.00	0.00	50.00	5,291.00
					64	R43V	422260	CHUI, WENZI	0.00	0.00	11.00	1,164.02
						R43V	619830	HOSMANE, B	0.00	0.00	9.00	952.38
						R43V	C090322	LOCKE, C	0.00	0.00	3.00	317.46
						R43V	130430	ZHANG, Y	0.00	0.00	19.00	2,010.58
						R43V	392290		11.00	1,164.02	92.00	9,735.44
								Department R43V Total:	11.00	1,164.02	92.00	9,735.44
						R4PK	401290	DUTTA, SANDEEP	8.00	908.80	65.00	7,384.00
						R4PK	261690	GRANNEMAN, RICHARD	6.00	681.60	6.00	681.60
						R4PK	398290	LEE, LILLIAN	0.00	0.00	16.00	1,817.60
						R4PK	309060	SCITWEITZER, SARAH	25.00	2,840.00	140.00	15,904.00
								Department R4PK Total:	39.00	4,430.40	227.00	25,787.20
								Division 64 Total:	50.00	5,594.42	319.00	35,522.64

CONFIDENTIAL
ABBT0578024

Page 3

COMprehensive Project Accounting SysTem
DINGII – Project Detail – December, 2002

R0025

Project Code	Project	Ben Code	Class Code	Tax Code	Div Code	Dept Code	Cost/Emp Code	Cost/Employee Description	Current Hours	Current Cost	YTD Hours	YTD Cost
143010	ABT-594 (CCM) Base Program	G0	2	Q	65	R420 R420	313830 323310	CHIRA, T RIPPA, JEANETTE	16.00 0.00	2,196.00 0.00	24.00 9.00	3,294.00 1,235.25
								Department R420 Total:	16.00	2,196.00	33.00	4,529.25
						R48K R48Q R48Q R48Q R48Q	263280 199030 603190 403670 427570	COLLICOIT, MARILYN VENTURE ABSORPTION FEIGE, CAROL KACOS, CATHERINE MATALONIS, ALDONA	0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00	0.00 1,814,143.36 0.00 0.00 0.00
								Department R48Q Total:	0.00	0.00	307.50	1,814,143.36
						R48U	603190	FEIGE, CAROL	0.00	0.00	101.50	0.00
								Division 65 Total:	16.00	2,196.00	448.00	1,818,672.61
						R4P6 R492 R492 R492	397320 454970 329390 200640	HARMAN, WHITNEY BANDERA, GISELA BENTLAGE, KEITH REIDMAN, PAMELA	0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00	4.00 8.00 6.00 1.00	519.36 1,038.72 779.04 129.84
								Department R492 Total:	0.00	0.00	15.00	1,947.60
143012	CCM ABT-594 I V -Acute	G0	2	Q	20	0491	295270	COSNER, SANDRA	101.00	7,736.00	2,028.75	1,390,759.60
143030	CCM ABT-259	G0	2	Q	20	0421 0421 0421 0421 0421	E91700 618760 C093805 319900 234500	MISC EXP COOKE, MARCIA DROBNICK, MARK TURK, PATRICIA M WRIGHT, JOSEPH	0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00	0.00 0.50 1.00 2.00 6.00	3,966.48 710.45 54.65 109.30 218.60 655.80
								Department 0421 Total:	0.00	0.00	9.50	1,748.80
						0491	436620	MURAOKA, LEE	0.00	0.00	16.00	2,266.56
								Division 20 Total:	0.00	0.00	25.50	4,015.36
					53	R44F R44F	091570 379140	KALLAL, THOMAS ORR, MICHAEL	0.00 0.00	0.00 0.00	7.00 20.00	991.62 2,813.20
								Department R44F Total:	0.00	0.00	27.00	3,824.82
						R4QE R4QE R4QE	598960 095570 379140	FRANZ, LISA JENSEN, MICHELLE ORR, MICHAEL	3.00 1.00 0.00	424.98 141.66 0.00	20.00 7.00 19.00	2,833.20 991.62 2,691.54
								Department R4QE Total:	4.00	566.64	46.00	6,516.36
								Division 53 Total:	4.00	566.64	73.00	10,341.18
								Project 143030 Total:	4.00	566.64	98.50	14,356.54
								Grand Total:	105.00	8,302.64	2,155.25	1,409,082.62

CONFIDENTIAL
ABBT0578025

2003

Global Pharmaceutical Research & Development
Global Development Project Expense Report
Project Group: ABT-492 Quinolone
Site: Global - All Sites
December, 2003 (000's)

December, 2003 (\$'000 \$)																					
Update		2003 Actuals												2003 Actual		2003 Actual		2003 Actual		Act vs	
YTD		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD		YTD		YTD			
W05 - WW Therapeutic Discovery		551	118	112	126	66	38	24	10	15	6	4	2	1	518		33				
W15 - WW Pre-clinical Safety		269	88	64	70	45	26	38	45	21	9	15	18	9	449		(180)				
W25 - WW Phase I Center		101	9	11	18	12	5	10	5	3	17	10	13	13	126		(25)				
W35 - WW Scientific Operations		0	0	0	0	373	0	0	0	0	0	0	0	0	373		(373)				
W45 - WW Global Project Teams		2,029	175	107	131	157	144	145	129	144	133	134	126	170	1,696		333				
W55 - WW Pharm Analytical R&D		285	151	54	69	32	30	26	27	42	8	4	11	6	461		(176)				
W65 - WW Regulatory Affairs		59	7	3	6	5	5	5	5	5	5	5	5	5	59		0				
W67 - WW GPCD Administration		0	1	1	2	2	0	1	2	4	1	2	0	3	19		(19)				
W75 - WW Services Sold		0	0	0	0	0	0	0	0	0	0	0	0	0	0		0				
TotWW		4,513	697	592	479	757	341	175	1,362	315	230	224	232	(1,342)	4,061		452				

COMMENTS
AI03MT
AI03MT
AI03MT
AI03MT
AI03MT
AI03MT

Global Pharmaceutical Research & Development
Global Development Project Expense Report
Project Group: ABB-724 (Dopamine-4 Agonist)
Site: Global - All Sites

December, 2003 (000's)															
Update	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	Act vs. Update		
YTD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	YTD	
W01 - WW Therapeutic Discovery	0	9	15	(2)	12	10	1	10	6	9	0	0	4	75	(75)
W02 - WW Therapeutic R&D	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W15 - WW Pre-clinical Safety	331	33	20	44	49	18	99	13	4	5	31	1	2	318	13
W20 - WW Phase I Clinical	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W25 - WW Phase I Center	57	1	1	1	6	3	0	4	0	0	0	0	1	17	40
W30 - WW Phase II Clinical	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W35 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W40 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W45 - WW Global Project Teams	75	0	0	0	0	0	0	0	0	0	0	0	0	0	75
W50 - WW Clinical Grants	220	0	0	0	0	0	0	0	0	0	0	0	0	0	220
W55 - WW Pharm Analytical R&D	80	21	5	10	5	4	2	0	1	1	0	0	0	51	40
W60 - WW Global Supply Mgmt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W65 - WW Regulatory Affairs	61	1	(1)	0	0	0	0	0	0	0	0	0	0	0	61
W70 - WW GPCD Administration	22	0	0	0	0	0	0	0	0	0	0	0	0	0	22
W75 - WW Global Supply Mgmt	6	4	1	0	0	1	0	0	0	0	0	0	0	6	2
W80 - WW Global Supply Mgmt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W85 - WW Global Supply Mgmt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W90 - WW Global Supply Mgmt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W95 - WW Global Supply Mgmt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W00 - WW Services Sold	752	301	120	111	79	43	107	39	14	22	33	4	(38)	834	(82)
TotWW															

COMMENTS

UR01DP
UR01CP
UR01DP
UR01DP
UR01DP
UR01DP

Global Pharmaceuticals, Research & Development
Global Development Project Expense Report
Project Group: ABT-751 (Eisai Anti-Mitotic)
Site: Global - All Sites

December, 2003 (USD \$)															Act vs. Update	
Update	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	YTD	YTD	
YTD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	YTD		
W05 - WW Therapeutic Discovery	149	4	12	12	8	21	8	18	37	19	12	36	39	228	(79)	
W15 - WW Pre-clinical Safety	676	27	59	74	67	115	59	63	72	66	70	64	66	805	(128)	
W25 - WW Phase I Center	279	0	12	8	26	30	2	20	5	11	2	14	20	152	127	
W35 - WW Scientific Operations	0	0	0	0	1	0	0	0	0	0	0	0	0	1	(1)	
W45 - WW Global Project Teams	2,121	170	144	186	191	195	177	169	157	215	177	193	234	2,208	(97)	
W55 - WW Pharm Analytical R&D	2,179	169	181	95	96	79	117	118	92	98	195	122	193	1,554	625	
W60 - WW Regulatory Affairs	76	0	13	6	6	6	6	6	6	6	6	6	6	77	(1)	
W65 - WW GPCD Administration	103	8	4	5	7	3	3	2	1	1	6	7	6	52	51	
W75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Total	10,681	627	1,310	964	701	816	671	1,011	1,095	1,006	1,385	1,341	82	11,007	(326)	

COMMENTS

CONCLUSIONS

CKINES

GNK NES

CRANKS

CRICKETS

CHICKEN'S

CONFIDENTIAL
ABBT0578030

**Global Pharmaceutical Research & Development
Global Development Project Expense Report
Project Group: ABT-773 Ketolide
Site: Global - All Sites
December, 2003 (000's)**

Update		December, 2003 (000's)												Act vs. Update	
YTD	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	2003 Actual	YTD	YTD
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD		YTD
W03 - WW Therapeutic Discovery	0	1	2	0	0	0	1	1	0	1	0	0	6	(6)	
W05 - WW Therapeutic Discovery	0	0	0	0	0	0	0	0	0	0	0	0	0		
W10 - WW Pre-clinical Safety	15	0	0	0	0	0	0	0	0	0	0	0	0		
W15 - WW Pre-clinical Safety	54	14	20	7	2	8	2	1	1	2	1	1	65	(11)	
W20 - WW Global Development	0	0	0	0	0	0	0	0	0	0	0	0	0		
W25 - WW Phase I Center	11	11	21	16	9	2	3	0	0	0	2	4	90	(79)	
W30 - WW Development Operations	82	24	24	19	0	0	0	0	0	0	0	0	0		
W35 - WW Scientific Operations	0	0	0	4	0	0	0	0	0	0	0	0	4	(4)	
W40 - WW Scientific Operations	370	33	20	25	29	27	24	27	25	25	24	32	318	52	
W45 - WW Global Project Teams	0	0	0	0	0	0	0	0	0	0	0	0	0		
W50 - WW Clinical Grants	0	0	0	0	0	0	0	0	0	0	0	0	0		
W55 - WW Pharm Analytical R&D	792	41	29	32	24	12	12	24	7	9	6	4	3	203	589
W57 - WW Global Development	0	0	0	0	0	0	0	0	0	0	0	0	0		
W60 - WW Regulatory Affairs	59	11	(1)	5	5	5	5	5	5	5	5	5	59	0	
W65 - WW Total Assets R&D	58	0	0	0	0	0	0	0	0	0	0	0	0		
W67 - WW GPCD Administration	38	3	1	6	7	2	1	4	2	3	3	6	39	(1)	
W70 - WW Global Development & New Bu	0	0	0	0	0	0	0	0	0	0	0	0	0		
W75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TotWW	1,702	201	199	199	195	(1,366)	196	47	(505)	77	46	88	(929)	2,631	

COMMENTS
AI02MC
AI02MC
AI02MC
AI02MC
AI02MC
AI02MC

Report Created: 01/14/2005 9:36 AM

CONFIDENTIAL
ABBT0578032

**Global Pharmaceutical Research & Development
Global Development Project Expense Report
Project Group: ABT-510 (TSP Peptide)
Site: Global - All Sites
December, 2004 (900's)**

	Update		RunRate		RunRate vs. Upd	
	Year	Year	Year	Year	Year	Year
WW1 - WW10 Project Grants	0	152	0	152	0	152
WW5 - WW Therapeutic Discovery	873	1,549	873	1,549	0	876
WW10 - WW Process R&D	2,924	2,899	2,924	2,899	0	1,176
WW5 - WW Pre-clinical Safety	2,188	2,821	2,188	2,821	0	633
WW9 - WW Global Medical Affairs	277	743	277	743	0	14
WW25 - WW Phase I Center	561	254	561	254	0	307
WW30 - WW Development Operations	1,271	1,743	1,271	1,743	0	575
WW35 - WW Scientific Operations	0	0	0	0	0	0
WW40 - WW Services Purchases	270	0	270	0	0	270
WW45 - WW Global Project Teams	3,280	3,024	3,280	3,024	0	238
WW50 - WW Clinical Grants	5,277	5,551	5,277	5,551	0	128
WW55 - WW Pharm Analytical R&D	3,851	3,122	3,851	3,122	0	529
WW60 - WW Global Clinical Support	1,629	1,151	1,629	1,151	0	478
WW65 - WW Regulatory Affairs	161	161	161	161	0	0
WW68 - WW Quality Assurance	373	407	373	407	0	374
WW67 - WW GPCD Administration	309	134	309	134	0	175
WW70 - WW Global Operations & New BU	0	0	0	0	0	0
WW75 - WW Services Sold	0	0	0	0	0	0
Total	23,499	23,598	23,499	23,598	0	(99)

COMMENTS
CNKNAG
CNKNAG
CNKNAG
CNKNAG
CNKNAG
CNKNAG

Global Pharmaceutical Research & Development
Global Development Project Expense Report
Project Group: ABT-627 (atrasentan)
Site: Global - All Sites
December 2004 (000's)

December, 2004 ('000's)																	Act vs. Update		
Update	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	M12YTD	M12YTD
M12YTD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	M12YTD	M12YTD	M12YTD	M12YTD	M12YTD	M12YTD	M12YTD
W01 - WW LU Project Costs	0	1	2	1	1	2	2	2	2	1	1	1	1	19	19	19	19	19	19
W05 - WW Therapeutic Discovery	1,431	33	45	62	75	72	57	77	78	92	93	187	212	1,082	349	349	349	349	349
W06 - WW Process R&D	1,410	30	31	31	9	10	25	100	143	37	78	143	22	1,496	920	920	920	920	920
W10 - WW Process R&D	1,410	30	31	31	9	10	25	100	143	37	78	143	22	1,496	920	920	920	920	920
W15 - WW Pre-clinical Safety	844	114	176	133	261	162	176	220	125	198	232	163	135	2,097	1,152	1,152	1,152	1,152	1,152
W20 - WW Global Medical Affairs	1,333	7	30	30	0	0	0	0	0	0	901	187	68	1,176	49	49	49	49	49
W25 - WW Phase I Center	724	30	74	58	114	74	79	66	42	28	48	46	38	698	26	26	26	26	26
W30 - WW Development Operations	2,786	21	25	233	303	268	203	419	130	385	302	228	229	3,513	2,717	2,717	2,717	2,717	2,717
W35 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W40 - WW Services Enriched	8,963	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W45 - WW Global Project Teams	8,963	0	27	0	926	4,897	1,068	1,264	856	1,020	766	719	11,531	2,568	2,568	2,568	2,568	2,568	2,568
W50 - WW Clinical Grants	16,175	1,012	1,032	1,192	1,119	1,009	1,511	1,511	1,592	1,295	1,710	1,495	14,293	1,882	1,882	1,882	1,882	1,882	1,882
W55 - WW Pharm Analytical R&D	7,199	242	234	232	284	332	347	483	563	551	542	349	367	4,526	2,674	2,674	2,674	2,674	2,674
W57 - WW Global Out Supply Mgmt	1,917	178	183	170	143	117	143	131	157	252	198	67	113	1,316	541	541	541	541	541
W60 - WW Regulatory Affairs	478	0	0	68	22	22	22	22	22	0	220	40	40	478	0	0	0	0	0
W65 - WW Quality Assurance	833	71	62	31	50	34	102	71	36	11	130	26	75	1,700	892	892	892	892	892
W67 - WW GPCD Administration	1,291	18	25	20	20	17	16	22	22	17	968	128	135	1,409	1,118	1,118	1,118	1,118	1,118
W70 - WW Global Licensing & New Bu	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total WW	45,560	2,064	2,206	2,005	2,356	3,152	5,862	4,028	4,040	4,031	5,952	4,055	3,670	43,423					

[illegible]

	Update	RunRate	RunRate vs. Upd
	Year	Year	Year
W01 - WW LU Project Costs	0	19	(19)
W05 - WW Therapeutic Discovery	1,431	1,082	349
W10 - WW Process R&D	1,416	293	1,220
W15 - WW Pre-clinical Safety	944	2,087	(1,152)
W20 - WW Global Medical Affairs	145	175	(30)
W25 - WW Phase I Center	724	888	28
W30 - WW Development Operations	2,756	1,133	1,777
W35 - WW Scientific Operations	0	0	0
W40 - WW Services and Support	459	0	459
W45 - WW Global Project Teams	8,963	11,531	(2,568)
W50 - WW Clinical Trials	6,175	1,253	4,922
W55 - WW Pharm Analytical R&D	7,199	4,526	2,674
W61 - WW Global Drug Supply Mgmt	1,917	1,576	341
W80 - WW Regulatory Affairs	478	478	0
W95 - WW Quality Assurance	533	523	10
W67 - WW GPCD Administration	1,291	1,409	(118)
W70 - WW Global Training & Development	0	0	0
W75 - WW Services Sold	0	0	0
Total WW	45,560	43,423	2,137

	Update M12YTD	December, 2004 ('000's)												Act vs. Updte M12YTD
		Actuals Jan	Actuals Feb	Actuals Mar	Actuals Apr	Actuals May	Actuals Jun	Actuals Jul	Actuals Aug	Actuals Sep	Actuals Oct	Actuals Nov	Actuals Dec	
WW1 - WW Global C&S	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW5 - WW Therapeutic Discovery	28	1	0	0	0	0	0	0	0	0	0	0	1	28
WW10 - WW Process R&D	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW15 - WW Pre-clinical Safety	0	0	0	2	5	0	1	0	0	1	0	1	0	11
WW20 - WW Global Medical Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW25 - WW Phase I Center	7	0	0	0	1	0	0	0	0	0	0	0	0	5
WW30 - WW Development Operations	31	0	0	0	4	0	0	6	16	6	2	3	0	(30)
WW35 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW40 - WW Services Purchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW45 - WW Global Project Teams	75	1	0	19	1	0	0	17	30	28	3	7	1	109
WW50 - WW Clinical Grants	0	0	0	0	50	0	0	10	0	0	2	0	0	(52)
WW55 - WW Pharm Analytical R&D	0	6	5	7	6	3	3	2	3	3	3	24	7	69
WW57 - WW Global Drug Supply Mgmt.	0	0	0	0	2	9	4	(2)	1	1	5	2	29	(28)
WW60 - WW Regulatory Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW63 - WW Quality Assurance	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW67 - WW GPCD Administration	0	3	1	0	1	1	1	2	0	0	0	1	1	10
WW70 - WW Global Licensing & New Bu.	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WW75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	423	14	12	30	71	14	8	23	49	(43)	11	41	30	260

	Update		RunRate		RunRate & Upd	
	Year	Year	Year	Year	Year	Year
W015 - WW U. Project Costs	0	0	0	0	0	0
W05 - WW Therapeutic Discovery	28	1	28	1	28	1
W020 - WW Process R&D	0	0	0	0	0	0
W15 - WW Pre-clinical Safety	0	11	0	11	0	11
W20 - WW Global Mfg. Affairs	0	0	0	0	0	0
W25 - WW Phase I Center	7	1	7	1	7	1
W30 - WW Development Operations	0	0	0	0	0	0
W35 - WW Scientific Operations	0	0	0	0	0	0
W40 - WW Services Purchased	0	0	0	0	0	0
W45 - WW Global Project Teams	75	109	75	109	75	109
W50 - WW Chemical Grants	0	0	0	0	0	0
W55 - WW Pharm Analytical R&D	0	69	0	69	0	69
W57 - WW Global Prod Supply Mgmt	0	0	0	0	0	0
W60 - WW Regulatory Affairs	0	0	0	0	0	0
W65 - WW Quality Assurance	0	0	0	0	0	0
W87 - WW GPCD Administration	0	10	0	10	0	10
W70 - WW Global Training & Development	0	0	0	0	0	0
W75 - WW Services Sold	0	0	0	0	0	0
To WW	423	260	423	260	423	260

COMMENTS
A102MC
A102MC
A102MC
A102MC
A102MC
A102MC

Global Pharmaceutical, Research & Development
Global Development Project Expense Report
Project Group: ABT.751 (Eisai Anti-Mitotic)
Site: Global - All Sites
December, 2005 (000's)

Plan	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals
N127TD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	M127TD	Actuals	Actuals	Actuals	Actuals	Actuals	Actuals
W01 - WW LU Project Costs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W05 - WW Therapeutic Discovery	36	36	39	24	46	52	44	52	39	51	152	170	740	740	740	740	740	740	740
W07 - WW Discovery IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W10 - WW Process Research & Deve	2,541	2	14	185	13	147	164	43	22	56	76	74	824	824	824	824	824	824	824
W13 - WW GPO (ABC)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W15 - WW Pre-Clinical Development	2,611	158	245	335	281	414	467	355	491	322	472	421	4,445	4,445	4,445	4,445	4,445	4,445	4,445
W20 - WW Development Operations	934	31	110	70	29	71	85	45	53	51	98	64	731	731	731	731	731	731	731
W25 - WW Experimental Medicine	702	27	53	43	37	25	41	31	55	47	13	44	28	442	442	442	442	442	442
W30 - WW Life Cycle Management	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W35 - WW Clinical Project Teams	4,445	26	0	558	344	94	440	25	164	242	250	363	3,128	3,128	3,128	3,128	3,128	3,128	3,128
W40 - WW Finance & Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W45 - WW Medical Affairs	37	9	9	6	7	5	7	0	0	13	2	6	72	72	72	72	72	72	72
W46 - WW Medical Services	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W47 - WW Quality Assurance	577	5	40	43	17	6	4	6	16	13	15	25	195	195	195	195	195	195	195
W49 - WW Clinical Grants	1,066	331	331	102	81	25	7	7	113	113	113	113	1,668	1,668	1,668	1,668	1,668	1,668	1,668
W50 - WW Development Management	82	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W53 - WW Regulatory Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W54 - WW Human Resources	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW PPG IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W65 - WW Services Purchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W85 - WW Other Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W88 - WW ECO External	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W91 - Japan Development	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total WW	12,485	627	838	1,616	853	791	1,259	624	501	838	1,072	1,646	1,249	12,321	12,321	12,321	12,321	12,321	12,321

CONFIDENTIAL
ABBT0578038

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

JOHN HANCOCK LIFE INSURANCE)	
COMPANY, JOHN HANCOCK VARIABLE)	
LIFE INSURANCE COMPANY, and)	
MANULIFE INSURANCE COMPANY (f/k/a)	
INVESTORS PARTNER LIFE INSURANCE)	
COMPANY),)	CIVIL ACTION NO. 05-11150-DPW
Plaintiffs,)	
)	
v.)	
)	
ABBOTT LABORATORIES,)	
)	
Defendants,)	

**ABBOTT LABORATORIES' AMENDED RESPONSES AND OBJECTIONS
TO PLAINTIFFS' SECOND SET OF INTERROGATORIES**

Defendant Abbott Laboratories ("Abbott"), by its undersigned counsel and pursuant to Rule 33 of the Federal Rules of Civil Procedure and Local Rules, hereby responds and objects the Second Set of Interrogatories of Plaintiffs John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Investors Partner Life Insurance Company's (collectively, "Hancock").

GENERAL OBJECTIONS AND RESPONSES

The following General Objections and Responses apply to each and every one of the numbered interrogatories below, and the General Objections and Responses shall be deemed continuing as to each interrogatory and are not waived, or in any way limited, by the specific objections and answers to any individual interrogatory.

1. Abbott objects to the "Definitions and Instructions" set forth in Hancock's interrogatories, as well as the interrogatories themselves, to the extent that

Hancock seeks to require Abbott to provide information beyond that required by the Federal Rules of Civil Procedure or Local Rules of the Court.

2. Abbott objects to each Interrogatory to the extent that it seeks information or documents protected by the attorney-client privilege, the work product doctrine, or any other applicable privileges.

3. Abbott objects to each and every Interrogatory to the extent that it is overly broad in scope or time and unduly burdensome.

4. Abbott objects to each and every Interrogatory to the extent that it calls for information that is not relevant to any of the claims or defenses in this litigation.

5. Abbott objects to each and every Interrogatory to the extent that it calls for information outside of Abbott's possession, custody, or control.

6. To the extent that Abbott responds to specific Interrogatories to which it has objected, Abbott's objections are not waived by the furnishing of such information and Abbott reserves the right to maintain such objections with respect to any additional information.

7. To the extent that Abbott responds to a specific Interrogatory, Abbott does not admit Plaintiffs' characterizations of any documents, facts, theories, or conclusions.

8. To the extent that Abbott responds to a specific Interrogatory, Abbott does not admit the relevance of such information to the subject matter of this litigation. Further, by responding to Hancock's interrogatories, Abbott is not waiving any applicable privileges nor shall the inadvertent disclosure of any privileged information operate as a waiver of any applicable privilege or immunity from discovery.

9. The responses to these Interrogatories are based on information currently known to Abbott and its current employees, and Abbott expressly reserves the right to supplement its responses to these Interrogatories with further additional information and documents as such information and documents become available to Abbott in the course of this litigation.

10. Except where specifically indicated below, the individuals identified in response to these interrogatories are all current or former employees of Abbott to be contacted only through counsel of record for Abbott herein.

11. Abbott objects to these interrogatories on the ground that in total, including all discrete subparts, they exceed the total number of interrogatories permitted by the Federal Rules of Civil Procedure, Local Rules and any Orders entered by the Court in this case.

Subject to these General Objections and Responses, and without waiving the same, Abbott states as follows:

SPECIFIC OBJECTIONS AND RESPONSES

15. Please state Abbott's actual spending on Program Related Costs for each Program Compound during each year of the four-year Program Term (i.e., 2001 through and including 2004), and during the subsequent year commencing immediately after the end of the Program Term (i.e., 2005).

Response: Abbott specifically objects to this interrogatory on the grounds that it is overly broad and unduly burdensome. Subject to these specific objections and its General Objections and Responses, and without waiving them, Abbott states that its actual spending on Program Related Costs for each of the Program Compounds for the period 2001-2005 is set forth below:

Number	Name	2001	2002	2003	2004	2005	Total
ABT-100	FTI	3.6	2.4	0.0	0.0	0.0	6.0
ABT-492	Quinolone	20.1	28.2	4.1	0.0	0.0	52.4
ABT-510	TSP #1	8.8	12.3	18.5	23.6	16.2	79.4
ABT-518	MMPI	3.7	0.0	0.0	0.0	0.0	3.7
ABT-594	Neuro Pain	7.8	1.4	0.0	0.0	0.0	9.2
ABT-627	Altrsentan Base	34.1	48.1	50.7	38.4	38.7	210.0
ABT-627	Altrsentan Hormone Naïve Prostate Cancer	0.0	1.2	2.5	2.3	3.3	9.3
ABT-627	Japan	0.0	0.1	0.2	1.5	1.5	3.3
ABT-627	Non-Prostate Cancers	0.0	0.0	0.2	1.0	0.9	2.1
ABT-724	Dopamine 4 Agonist	3.2	5.5	0.8	0.0	0.0	9.5
ABT-751	Anti-Mitotic	6.5	9.6	11.0	13.5	12.3	52.9
ABT-773	Base	80.3	13.8	(0.9)	0.3	0.0	93.5
ABT-773	Japan	1.4	1.9	0.0	0.0	0.0	3.3
	Total	169.5	124.5	87.1	80.6	72.9	534.6

Amended Response: Abbott specifically objects to this interrogatory on the grounds that it is vague, ambiguous, overly broad and unduly burdensome. Subject to these specific objections and its General Objections and Responses, and without waiving them, Abbott responds as follows:

After meeting and conferring with Hancock, Abbott agreed to amend its response to this interrogatory to state its actual monthly spending on each of the Program Compounds in January, February, and March 2001. In the course of preparing its amended interrogatory response, Abbott discovered some inadvertent errors in its original response. Abbott's corrected actual calendar year spending on Program Related Costs for each of the Program Compounds for the period 2001-2005 is set forth below:

Number	Name	2001	2002	2003	2004	2005	Total
ABT-100	FTI	9.2	2.4	0.0	0.0	0.0	11.6
ABT-492	Quinolone	23.1	32.8	4.1	0.0	0.0	60.0
ABT-510	TSP #1	8.8	12.8	18.5	23.6	16.1	79.8

ABT-518	MMPI	3.7	0.0	0.0	0.0	0.0	3.7
ABT-594	Neuro Pain	7.8	1.4	0.0	0.0	0.0	9.2
ABT-627	Altrasentan Base	34.1	51.8	53.6	43.4	44.6	227.5
ABT-627	Altrasentan Hormone Naïve Prostate Cancer	-	-	-	-	-	-
ABT-627	Japan	-	-	-	-	-	-
ABT-627	Non-Prostate Cancers	-	-	-	-	-	-
ABT-724	Dopamine 4 Agonist	8.1	6.5	0.8	0.0	0.0	15.4
ABT-751	Anti-Mitotic	6.5	9.7	11.0	13.5	12.3	53.0
ABT-773	Base	80.8	13.9	(0.9)	0.3	0.0	94.1
ABT-773	Japan	-	-	-	-	-	-
	Total	182.1	131.3	87.1	80.8	73.0	554.3

Abbott's actual monthly expenditures on each Program Compound in 2001 are reflected in the Abbott expense reports attached hereto as Exhibit A. Please note that expenditures on the ED Program (ABT-724) are the sum of the expenditures reported on pages A-38 and B-4. Abbott also is producing concurrently with this amended interrogatory response expense reports reflecting the actual expenditures on each Program Compound from 2002 through 2005.

In addition to the expenditures that are listed above and in the attached expense reports, Abbott made management fee and/or milestone payments to Hancock in the amount of \$10 million in 2002, \$2 million in 2003, and \$2 million in 2004, which constitute Program Related Costs under Section 1.43 of the Research Funding Agreement.

16. Please state whether any of the representations or warranties made by Abbott in Section 12.2 of the Research Funding Agreement were untrue or inaccurate in any way as of March 13, 2001.

Response: Abbott specifically objects to this interrogatory on the grounds that it is grossly compound, overly broad and unduly burdensome. Because Section 12.2 of the Research Funding Agreement incorporates by reference nine other documents, containing hundreds of sentences, the task of determining whether any of the

representations or warranties made in Section 12.2 are “untrue” or “inaccurate” “in any way” is unduly burdensome. Moreover, if every sentence in Section 12.2 and the documents incorporated therein are considered representations and warranties, the request exceeds the number of interrogatories permitted (including subparts) in this litigation. Abbott also objects to this interrogatory because it seeks information protected from disclosure under the attorney-client privilege and attorney work product doctrine. This interrogatory seeks, *inter alia*, Abbott’s legal analysis and conclusions as to which statements contained in the numerous documents attached to the Agreement and incorporated into Section 12.2 constitute a representation or warranty and also whether or not any such representations or warranties were untrue or inaccurate in any way. As a result, this interrogatory cannot be answered without disclosing attorney work product and attorney-client privileged communications, and any response by Abbott would be intertwined with the mental impressions, conclusions, opinions, and legal theories of its counsel as a result of its investigation of the claims made by Hancock in this case. Finally, Abbott objects to this interrogatory on the ground that it attempts improperly to shift the burden of proof from Hancock to Abbott on Hancock’s claims in this case.

17. If your answer to Interrogatory No. 16, supra, is anything other than an unqualified negative, please state in as much detail as reasonably possible which specific representations or warranties made by Abbott in Section 12.2 of the Research Funding Agreement were untrue or inaccurate as of March 13, 2001 and why.

Response: Abbott incorporates by reference its response to Interrogatory No. 16.

ABBOTT LABORATORIES

By its attorneys


Eric J. Lorenzini

Jeffrey I. Weinberger (Admitted Pro Hac Vice)
Gregory D. Phillips (Admitted Pro Hac Vice)
Eric J. Lorenzini (Admitted Pro Hac Vice)
Ozge Guzelsu (Admitted Pro Hac Vice)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
(213) 683-9100

and

Michael S. D'Orsi
Peter E. Gelhaar (BBO #188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY & GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880

Dated: Aug. 3, 2007

VERIFICATION

I, Kenneth Stiles, state under penalties of perjury that: I am Assistant Controller for Global Pharmaceutical Research and Development at Abbott Laboratories ("Abbott"). I have read the foregoing responses to interrogatories and know the contents thereof, that said answers were prepared with the assistance and advice of counsel and employees of Abbott; that the responses set forth herein, subject to inadvertent or undiscovered errors, are based on and therefore necessarily limited by the records and information still in existence, presently collected and thus far discovered in the course of the preparation of these answers; that Abbott reserves the right to make any changes in the responses if it appears at any time that omissions or errors have been made therein or that more accurate information is available; and that, subject to the limitations set forth herein, the responses are true to the best of my knowledge, information and belief.

Interrogatory answers signed under the pains and penalties of perjury this
3rd day of August, 2007.



Kenneth Stiles

Exhibit A

28-Jan-02
PAGE A-11

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DISCOVERY PROJECT EXPENSE REPORT
FARNESYLTRANSFERASE

	MONTHLY RESULTS												YTD Approved APU	YTD Total	Yr.
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery Administrative Overhead	69	68	69	69	68	69	69	68	69	69	68	69	824	824	...
Discovery Functional	240	243	259	255	210	233	215	208	209	219	221	226	2,738	2,756	18
Discovery Svc. Profit/Sold-Internal	265	299	442	446	429	502	390	473	252	151	233	217	4,099	3,061	(1,038)
Discovery Service Sold-External
Total Discovery (less overhead)	505	542	701	701	639	735	605	681	461	370	454	443	6,837	5,817	(1,020)
Drug Safety															
Metabolism	17	18	25	29	32	63	55	39	21	26	25	21	371	416	45
Toxicology/Pathology	22	25	28	26	16	43	28	19	37	9	10	63	326	163	(163)
Comparative Medicine	34	60	129	121	41	100	25	34	7	14	20	26	611	554	(57)
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services
Phase-IV
Phase-I Center
Clinical
ACPRU - Direct	10	10	10
Development Operations
Data Management
Biostatistics
Research Information Cir	1	1	9	10	1	22	14	(8)
Information Mgmt & Tech	1	1	(3)
International Manpower
Grants - Domestic
R&D Project Services
International Directors
Venture Management
PARD
Regulatory Affairs	1	1	1	23	47	40	21	...	22	25	15	26	221	21	(200)
Research QA	5	1	6	6	(6)
Investigational Drug QA
SPD
Genet Credit
Other
Judgment
Total	649	716	983	970	843	1,059	815	841	617	515	592	648	9,218	7,819	(1,399)

COMMENTS

CONFIDENTIAL
ABBT0578006

28-Jan-02
PAGE B-10

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
QUINOLONE ABT492

	MONTHLY RESULTS												YTD Approved ΔPJ	YTD Total	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	220	327	355	488	246	229	88	251	86	287	186	88	2,851	2,829	(22)
Drug Safety															
Metabolism	55	114	194	111	127	142	110	112	84	61	71	75	1,256	910	(346)
Toxicology/Pathology	28	53	50	61	134	108	57	40	26	24	28	29	638	1,375	737
Comparative Medicine	1	38	36	23	39	29	22	19	23	28	26	26	310	117	(193)
Strategic and Exploratory															
Medical Affairs															
Outcomes Res/Admin															
Medical Services	4	3	4	4	4	4	3	4	3	4	4	4	45	41	(4)
Phase-IV															
Phase-I Center															
Clinical	3	4	6	12	19	15	19		44	9	14	10	155	279	124
ACPRU - Direct								12		88			100	83	(17)
Development Operations															
Data Management	14	38	25	38	20	15	10	21	14	18	22	17	252	374	122
Biostatistics	11	10	39	22	29	35	16	26	19	13	19	13	252	309	57
Research Information Cir	1	6	10	2	3	(22)									
Information Mgmt & Tech															
International Manpower	71	41	52	75	96	77	248	110			(358)		412	409	(3)
Grants - Domestic	170	(40)	152	152	152	290	464	464	463	755	572	603	4,197	5,000	803
R&D Project Services		3	1	1	1	7	1			231	(51)	(14)	179		(179)
International Directors	8	8	11	5	3	9	5	10	5				64	53	(11)
Venture Management	124	118	132	214	(58)	107	124	70	97	100	120	74	1,222	1,123	(99)
PARD	115	179	185	203	207	271	202	189	241	225	597	114	2,228	951	(1,277)
Regulatory Affairs	5	6	3	5	9	46	5	27	17	24	16	11	174	100	(74)
Research QA	6		9	2	17	22	1	14	11	8	6	18	114	322	208
Re-org															
Investigational Drug QA	3	1	2	2	4	6	2	17	15	5	9		66	152	86
SPD	280	280	297	295	366	371	716	476	521	606	377	456	5,041	5,978	937
License Pymt/Royalty										3,000			3,000	2,600	(400)
Other														83	83
Judgment		3											3	(192)	(195)
Total	1,119	1,192	1,563	1,715	1,417	1,761	2,093	1,862	1,689	5,486	1,658	1,524	23,059	22,897	(162)

COMMENTS:

A) Unfavorable PARD variance due to effort on impurity and color issues, as well as an apparent underestimate of the required effort in the April Update.

CONFIDENTIAL
ABBT0578007

28-Jan-02
PAGE B-19

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
TSP PEPTIDE ABTS10

	MONTHLY RESULTS												YTD	
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	Approved APU
Discovery	71	140	252	161	70	98	71	83	63	61	101	76	1,247	1,704
Drug Safety														457
Metabolism	24	43	46	8	39	45	25	8	21	31	43	33	366	1,045
Toxicology/Pathology	2	10	2	6	14	20	(21)	2	2	6	1	1	45	164
Comparative Medicine	...	1	5	1	3	9	2	3	15	...	1	1	41	(41)
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services	1	1	1	...	1	1	1	1	1	1	...	1	10	9
Phase-IV
Phase-I Center
Clinical	10	14	28	20	29	30	19	...	29	13	9	8	209	205
ACPRU - Direct
Development Operations
Data Management	7	6	6	9	3	14	11	13	8	10	9	5	101	88
Biostatistics	2	7	5	19	21	12	7	6	11	18	1	6	115	120
Research Information Cir	...	1	1	5	11	(18)
Information Mgmt & Tech
International Manpower
Grants - Domestic	115	116	49	78	77	77	110	111	111	111	44	111	1,110	1,444
R&D Project Services	...	1	2	3	2	1	1	...	12	9
International Directors	1	1	1	...	2	3	3	2	2	15	29
Venture Management	61	58	56	108	25	36	20	140	63	72	58	92	789	756
PARD	55	158	133	136	98	204	94	114	73	118	117	94	1,394	1,139
Regulatory Affairs	1	3	...	6	4	25	5	3	3	10	3	1	64	74
Research QA	9	3	14	6	13	4	5	6	1	5	5	2	73	56
Re-org
Investigational Drug QA	2	2	1	3	3	3	3	4	12	...	1	4	38	52
SPD	187	185	203	205	259	253	307	300	391	258	247	369	3,164	3,383
License Pymt/Royalty
Other	...	1	1	(2)
Judgment
Total	548	751	805	771	672	816	661	795	807	719	643	806	8,794	10,275
	=====	=====	=====	=====	=====	=====	=====	=====	=====	=====	=====	=====	=====	=====

COMMENTS

- A) Increase due to higher manufacturing costs at Cook.
B) Delay in ROSS submissions and 5 month extension of end date for M01-302.

CONFIDENTIAL
ABBT0578008

28-Jan-02
PAGE 8-18

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
MMPI DEVELOPMENT ABT770/ABTS18

	MONTHLY RESULTS												YTD		Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	YTD Total	Approved APL	
Discovery	22	77	107	151	76	163	10	13	16	10	3	...	648	948	300
Drug Safety	77	95	99	50	47	34	45	6	4	5	15	21	498	480	(18)
Metabolism	117	164	122	139	83	23	(5)	(2)	1	5	12	2	661	713	52
Toxicology/Pathology	28	29	21	15	4	97	111	14
Comparative Medicine	17	24	12	21	1	(75)
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services
Phase-IV	50	(50)	10	9	(1)
Phase-I Center
Clinical	1	3	5	3	3	1	1	...	2	2	1	1	23	119	96
ACPRU - Direct
Development Operations	4	4	9	12	11	8	2	4	1	3	2	1	61	56	(5)
Data Management	1	2	8	2	4	8	1	2	1	29	47	18
Biostatistics	2	3	3	3	...	(11)
Research Information Ctr
Information Mgmt & Tech	16	1	2	2	2	...	6	1	(7)	23	23	...
International Manpower	64	64	64	64	64	64	64	(248)	200	200	...
Grants - Domestic
R&D Project Services
International Directors	70	66	65	123	27	42	23	160	72	82	66	106	902	805	(97)
Venture Management	42	54	75	30	40	41	22	18	19	2	2	4	349	349	0
PARD	5	6	6	2	1	12	1	2	2	3	2	2	44	72	28
Regulatory Affairs	13	3	15	8	10	5	...	4	5	9	5	2	79	70	(9)
Research QA
Re-org
Investigational Drug QA	1	5	3	4	...	4	1	...	1	...	19	23	4
SPD	28	...	1	29	...	(29)
License Pymt/Royalty
Other
Judgment	363	363
Total	481	603	621	682	326	321	176	(39)	120	153	111	142	3,697	4,414	717

Program Discontinued

COMMENTS

CONFIDENTIAL
ABBT0578009

	MONTHLY RESULTS												YTD		
													YTD Total	YTD Approved APU	Ytd
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	5	10	5	11	4	4	4	8	22	1	1	1	72	71	(1)
Drug Safety															
Metabolism	21	47	65	68	41	31	14	13	1		6	11	320	549	229
Toxicology/Pathology	87	128	159	96	(24)	63	11	31	31		15	26	645	694	49
Comparative Medicine	2					1	1						4	30	26
Strategic and Exploratory															
Medical Affairs															
Outcomes Res/Admin															
Medical Services	1	1	1	1	1	1	1	1	1	1	1	1	34	34	34
Phase-IV									2			2	10	9	(1)
Phase-I Center															
Clinical	16	13	34	18	21	48	12		17	4			184	349	165
ACPRU - Direct														207	207
Development Operations															
Data Management	19	30	56	24	7	3	4	3	2				149	243	94
Biostatistics	25	31	43	37	51	36	11	11	5	11	3	8	272	129	(143)
Research Information Ctr	2	3	7	1	5	(18)								124	124
Information Mgmt & Tech															
International Manpower	4			1											
Grants - Domestic	100												5	9	4
R&D Project Services						3			2		1	(8)	100	100	
International Directors														39	39
Venture Management	655	339	357	911	(565)	329	320	381	340	303	304	494	4,168	3,655	(513)
PARD	169	193	213	151	146	204	78	88	51	32	10	21	1,356	1,048	(308)
Regulatory Affairs	1	1	2	2	4	35	10	4	3	4	2	6	74	132	58
Research QA	14	19	16	10	19	12	6	19	5	3	4	2	129	81	(48)
Re-org															
Investigational Drug QA	2		1					1			1	(1)	4	75	71
SPD			28	47	31	36	127	36	31	(70)	31	31	328	357	29
License Pymt/Royalty															
Other															
Judgment															
Total	1,123	817	988	1,377	(259)	788	603	609	491	310	393	581	7,821	8,210	389

COMMENTS

A) Unfavorable variance due to milestone budgeting. The Plan is for 6 months of work, while the system projects it over 12 months. Venture is currently reviewing the Phase II results to determine what further funding may be required. Currently, the venture is at a "no-go" decision. If a "no-go" decision is granted, the venture has identified approx. \$1.5MM in expenses that would not be incurred. If a "go" decision is granted, approx. \$.9MM would be required to fund the project for the rest of the year.

CONFIDENTIAL
ABBT0578010

28-Jan-02
PAGE 8-17

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
ENDOTHELIN ABT627

	MONTHLY RESULTS												YTD		YTD	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	Approved		
Discovery	7	13	23	9	14	3	2	4	32	49	41	26	223	160	(63)	
Drug Safety																
Metabolism	31	51	24	37	46	19	47	56	21	18	27	43	420	991	571	
Toxicology/Pathology		3			3	4	3			5		3	21	349	328	
Comparative Medicine	3												3	26	23	
Strategic and Exploratory																
Medical Affairs																
Outcomes Res/Admin	11	35	30	26	38	6	22	25	28	14	16	53	304	259	(45)	
Medical Services	16	17	16	16	16	16	17	16	16	16	16	17	195	178	(17)	
Phase-IV													183		(183)	
Phase-I Center																
Clinical	20	32	27	12	30	47	30	(14)	56	62	(14)	12	300	579	279	
ACPRU - Direct											6		6	696	690	
Development Operations																
Data Management	56	51	68	48	55	37	34	33	31	53	28	51	545	1,596	1,051	
Biostatistics	79	92	80	109	67	68	60	74	56	55	62	64	866	743	(123)	
Research Information Ctr	5	7	11	4	5	(32)										
Information Mgmt & Tech																
International Manpower	22	12	15	17	15	17	3	3	(6)				98	170	72	
Grants - Domestic	1,035	1,035	1,035	1,035	776	1,018	1,033	1,944	1,943	1,943	1,719	2,855	17,371	18,044	673	
R&D Project Services	13	7	9	12		10	7	3	4	5	2	(72)		22	22	
International Directors	10	11	32	28	29	23	23	42	25	28	22	11	284	154	(130)	
Venture Management	548	506	504	950	216	1,413	712	(249)	571	648	459	713	6,991	6,596	(395)	
PARC	217	342	429	253	538	553	311	413	378	365	385	955	5,139	3,562	(1,577)	
Regulatory Affairs	17	13	13	25	16	49	14	22	14	24	21	18	246	415	169	
Research QA	31	14	15	29	27	12	44	8	11	5	27	4	227	428	201	
Re-org																
Investigational Drug QA	15	11	24	14	22	16	19	16	9	19	13	18	196	262	66	
SPD	41	41	41	40	(146)	41	41	40	226	41	43	40	489	683	194	
License Pymt/Royalty																
Other																
Judgment														(40)	(40)	
Total	2,177	2,293	2,396	2,664	1,767	3,320	2,422	2,436	3,415	3,350	2,873	4,994	34,107	35,874	1,767	

COMMENTS

- A) Increase in PARC due to last minute charges from Cook.
 B) Accrual for M00-244 delayed 1 month/1 month delay in ROSS submission M01-304, offset by accelerated spending
 C) M01-283 Qtc study on hold

CONFIDENTIAL
ABBT0578011

28-Jan-02
PAGE A.38

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DISCOVERY PROJECT EXPENSE REPORT
ERECTION DYSFUNCTION

	MONTHLY RESULTS												YTD Approved APU	YTD Total	YTD Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery Administrative Overhead	65	65	65	65	65	64	65	65	65	65	65	65	779	779	..
Discovery Functional	185	199	179	182	188	187	249	251	230	225	253	234	2,220	2,562	(342)
Discovery Svc Prch/Sold-Internal	154	379	344	366	348	468	271	117	91	129	99	80	1,672	2,846	(1,174)
Discovery Service Sold-External
Total Discovery (less overhead)	339	578	523	548	536	655	530	368	321	354	352	314	3,892	5,408	(1,516)
Drug Safety
Metabolism	14	21	52	72	46	49	26	29	24	34	27	22	304	416	(112)
Toxicology/Pathology	2	9	12	20	43	23	4	19	8	18	11	94	2	263	(261)
Comparative Medicine	50	23	73	64	48	49	54	47	38	46	45	48	934	585	349
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services
Phase-IV
Phase-I Center
Clinical
ACPRU - Direct
Development Operations
Data Management
Biostatistics
Research Information Ctr
Information Mgmt & Tech
International Manpower
Grants - Domestic
R&D Project Services
International Directors
Venture Management
PARD
Regulatory Affairs
Research QA
Investigational Drug QA
SPD
Genet Credit
Other
Judgment
Total	471	696	725	771	741	842	667	530	488	520	580	543	5,922	7,464	(1,542)

COMMENTS

CONFIDENTIAL
ABBT0578012

28-Jan-02
PAGE B-4PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
DOPAMINE

	MONTHLY RESULTS												YTD Approved APU	YTD Total	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	83	29	3	72	187	...	(187)
Drug Safety
Metabolism
Toxicology/Pathology	(121)
Comparative Medicine	(30)
Strategic and Exploratory	(28)
Medical Affairs
Outcomes Res/Admin
Medical Services	7	3	9	...	19	...	(19)
Phase-IV
Phase-I Center
Clinical
ACPRU - Direct	4	5	9	...	(9)
Development Operations
Data Management
Biostatistics
Research Information Ctr
Information Mgmt & Tech
International Manpower
Grants - Domestic
R&D Project Services
International Directors
Venture Management
PARC	12	64	89	60	225	...	(225)
Regulatory Affairs
Research QA
Re-org
Investigational Drug QA
SPD
License Pymt/Royalty
Other
Judgment
Total	106	118	143	261	628	...	(628)

COMMENTS

CONFIDENTIAL
ABBT0578013

28-Jan-02
PAGE B-20

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
EISAI ABT-751

	MONTHLY RESULTS												YTD		Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	Approved	
Discovery	22	24	22	11	8	21	4	31	19	25	7	1	195	193	(2)
Drug Safety	4	1	2	32	2	4	13	40	32	30	40	45	245	694	449
Metabolism	2	6	24	57	17	23	18	8	17	6	5	1	184	202	18
Toxicology/Pathology	1	...	6	3	1	...	11	103	92
Comparative Medicine
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services
Phase-IV	...	2	1	...	1	1	1	1	1	...	1	1	10	9	(1)
Phase-I Center
Clinical	1	2	2	4	2	2	1	...	7	2	2	15	40	118	78
ACPRU - Direct
Development Operations
Data Management	1	2	2	1	4	10	8	5	8	11	52	73	21
Biostatistics	1	...	1	1	1	2	...	1	1	3	11	81	70
Research Information Ctr	(1)
Information Mgmt & Tech
International Manpower	4
Grants - Domestic	1
R&D Project Services	...	2	2	3	...	2	2	1	...	112	112	(1)	4	8	4
International Directors	1	...	(13)	549	945	396
Venture Management	200	190	187	353	80	121	66	461	208	234	188	305	2,593	2,577	(16)
PARD	139	191	242	127	85	93	52	117	110	136	139	152	1,583	1,231	(352)
Regulatory Affairs	...	1	...	4	3	7	2	3	1	2	3	...	26	73	47
Research QA	2	4	2	3	4	2	2	1	20	48	28
Re-org
Investigational Drug QA	...	4	11	7	4	4	1	5	36	153	117
SPD	76	84	76	75	75	75	105	75	75	75	75	78	944	1,172	228
License Pym/Royalty
Other
Judgment
Total	450	507	579	683	281	353	274	755	479	634	583	925	6,503	7,681	1,178

A) Delay in ROSS submission M00-231 & M01-303

COMMENTS

CONFIDENTIAL
ABBT0578014

28-Jan-02
PAGE B-8

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
KETOLIDE ABT773

	MONTHLY RESULTS												YTD		YTD	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	Approved		
Discovery	185	219	269	210	234	296	210	271	214	284	258	84	2,734	2,419	(315)	
Drug Safety	45	76	105	94	97	103	42	67	98	157	130	140	1,154	1,006	(148)	
Metabolism	9	43	46	93	174	24	16	23	20	7	11	4	470	674	204	
Toxicology/Pathology	48	51	56	21	12	..	5	15	13	27	15	23	286	46	(240)	
Comparative Medicine	
Strategic and Exploratory	
Medical Affairs	
Outcomes Res/Admin	..	2	2	1	26	7	3	6	8	2	8	12	77	100	23	
Medical Services	70	69	70	69	70	70	70	69	69	70	70	69	835	696	(139)	
Phase-IV	
Phase-I Center	
Clinical	55	102	63	97	72	69	39	21	358	112	(192)	35	831	957	126	
ACPRU - Direct	155	264	108	258	..	190	260	102	1,337	1,040	(297)	
Development Operations	
Data Management	51	92	154	159	208	206	162	207	123	167	191	154	1,874	3,033	1,159	
Biostatistics	65	66	89	93	103	94	78	87	89	74	106	75	1,019	1,252	233	
Research Information Cur	33	35	51	57	30	(206)	
Information Mgmt & Tech	
International Manpower	172	151	146	200	230	159	279	129	167	..	(575)	..	1,058	979	(79)	
Grants - Domestic	5,541	5,541	5,432	5,605	5,608	5,605	200	(23)	162	2,401	2,414	7,710	46,197	47,031	834	
R&D Project Services	7	6	7	6	..	14	5	13	8	8	9	239	322	142	(180)	
International Directors	74	67	97	77	68	87	40	53	61	45	55	50	774	456	(318)	
Venture Management	619	588	661	1,072	(292)	537	620	348	483	500	598	375	6,109	5,310	(799)	
PARD	343	459	643	765	575	544	477	523	257	543	1,231	998	7,358	4,899	(2,459)	
Regulatory Affairs	4	18	15	8	13	262	41	58	35	20	43	29	546	450	(96)	
Research QA	28	23	76	63	36	89	63	85	40	20	28	30	581	446	(135)	
Re-org	
Investigational Drug QA	17	33	26	28	17	17	6	12	6	14	20	15	211	417	206	
SPD	908	564	2,581	134	(1,912)	555	1,939	113	602	601	464	464	7,013	13,770	6,757	
License Pymt/Royalty	
Other	
Judgment	..	2	315	4	(319)	2	533	(519)	
Total	8,429	8,471	10,697	8,853	5,369	8,532	4,295	2,335	2,813	5,557	5,146	10,289	80,788	85,136	4,348	

COMMENTS

- A) Unfavorable variance due to omission of a dog study in the April Update by Comparative Medicine.
 B) Decrease in Clinical Grant expense reflects increase in duration of Phase III studies.
 C) Favorable SPD variance reflects delay in receipt of bulk drug.

CONFIDENTIAL
ABBT0578015

PROOF OF SERVICE

I, Marie A. Contreras, declare:

1. I am over the age of 18 and not a party to the within cause. I am employed by Munger, Tolles & Olson LLP in the County of Los Angeles, State of California. My business address is 355 South Grand Avenue, Suite 3500, Los Angeles, California 90071-1560.


2. On August 3, 2007, I served the original and/or a true and correct copy of the document entitled **ABBOTT LABORATORIES' AMENDED RESPONSES AND OBJECTIONS TO PLAINTIFFS' SECOND SET OF INTERROGATORIES** on the interested parties in this action by placing a true copy thereof enclosed in a sealed envelope, mailed as marked below, and addressed as follows:

See Attached Service List

- ☒ **U.S. Mail:** I am "readily familiar" with the firm's practice of collection and processing correspondence for mailing. Under that practice it would be deposited with the U.S. postal service on that same day with postage thereon fully prepaid at Los Angeles, California in the ordinary course of business. I am aware that on motion of the party served, service is presumed invalid if postal cancellation date or postage meter date is more than one day after date of deposit for mailing affidavit.
- ☐ **Federal Express:** I am "readily familiar" with the firm's practice of collection and processing correspondence for delivery to an employee of Federal Express. Under that practice it would be delivered to an employee of Federal Express on that same day at Los Angeles, California with charges to be billed to Munger, Tolles & Olson LLP's account to be delivered to the offices of the addressee(s) on _____ in the ordinary course of business.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on August 3, 2007, at Los Angeles, California.



Marie A. Contreras

SERVICE LIST

Hancock, et al. v. Abbott Laboratories
Case No. 05-11150-DPW

Joseph H. Zwicker
Choate, Hall & Stewart LLP
Two International Place
Boston, MA 02110
Telephone: (617) 248-5076
Facsimile: (617) 248-4000
Email: jzwicker@choate.com

Michael S. D'Orsi
Donnelly, Conroy & Gelhaar, LLP
1 Beacon Street
33rd Floor
Boston, MA 02108
Telephone: (617) 720-2880
Facsimile: (617) 720-3554
Email: msd@dcglaw.com

28-Jan-02
PAGE A-11PHARMACEUTICAL PRODUCTS R&D
GLOBAL DISCOVERY PROJECT EXPENSE REPORT
FARNESYLTRANSFERASE

	MONTHLY RESULTS												YTD Approved APU	YTD Total	Var.
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery Administrative Overhead	69	68	69	69	68	69	69	68	69	69	68	69	824	824	..
Discovery Functional	240	243	259	255	210	233	215	208	209	219	221	226	2,738	2,738	18
Discovery Svc Preh/Solid-Internal	265	299	442	446	429	502	390	473	252	151	233	217	4,099	4,099	(1,038)
Discovery Service Solid-External
Total Discovery (less overhead)	505	542	701	701	639	735	605	681	461	370	454	443	6,837	6,837	(1,020)
Drug Safety
Metabolism	17	18	25	29	32	63	55	39	21	26	25	21	371	371	45
Toxicology/Pathology	22	25	28	26	16	43	28	19	37	9	10	63	326	326	(163)
Comparative Medicine	34	60	129	121	41	100	25	34	7	14	20	26	611	611	(57)
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services
Phase-IV
Phase-I Center
Clinical
ACPRU - Direct	10	10	10
Development Operations
Data Management
Biostatistics	1	1	1	1	1	9	10	1	22	22	(8)
Research Information Ctr	1	1	1	1	1	(3)
Information Mgmt & Tech
International Manpower
Grants - Domestic
R&D Project Services
International Directors
Venture Management
PARO	..	1	1	23	47	40	21	..	22	25	15	26	221	221	(200)
Regulatory Affairs	5	1	6	6	(6)
Research QA
Investigational Drug QA
SPD
Genet Credit
Other
Judgment
Total	649	716	953	970	843	1,059	815	841	617	515	592	648	9,218	7,819	(1,399)

COMMENTS

CONFIDENTIAL
ABBT0578006

28-Jan-02
PAGE B-10

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
QUINOLONE ABT492

	MONTHLY RESULTS												YTD Total	YTD Approved APU	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	220	327	355	488	246	229	88	251	86	287	186	88	2,851	2,829	(22)
Drug Safety															
Metabolism	55	114	194	111	127	142	110	112	84	61	71	75	1,256	910	(346)
Toxicology/Pathology	28	53	50	61	134	108	57	40	26	24	28	29	638	1,375	737
Comparative Medicine	1	38	36	23	39	29	22	19	23	28	26	26	310	117	(193)
Strategic and Exploratory															
Medical Affairs															
Outcomes Res/Admin															
Medical Services	4	3	4	4	4	4	3	4	3	4	4	4	45	41	(4)
Phase-IV															
Phase-I Center	3	4	6	12	19	15	19		44	9	14	10	155	279	124
Clinical								12		88			100	83	(17)
ACPRU - Direct															
Development Operations															
Data Management	14	38	25	38	20	15	10	21	14	18	22	17	252	374	122
Biostatistics	11	10	39	22	29	35	16	26	19	13	19	13	252	309	57
Research Information Ctr	1	6	10	2	3	(22)									
Information Mgmt & Tech															
International Manpower	71	41	52	75	96	77	248	110					412	409	(3)
Grants - Domestic	170	(40)	152	152	152	290	464	464	463	755	572	603	4,197	5,000	803
R&D Project Services		3	1	1	1	7	1			231	(51)	(14)	179		(179)
International Directors	8	8	11	5	3	9	5	10	5				64	53	(11)
Venture Management	124	118	132	214	(58)	107	124	70	97	100	120	74	1,222	1,123	(99)
PARD	115	179	185	203	207	271	202	189	241	225	597	114	2,728	951	(1,777)
Regulatory Affairs	5	6	3	5	9	46	5	27	17	24	16	11	174	100	(74)
Research QA	6		9	2	17	22	1	14	11	8	6	18	114	322	208
Re-org	3	1	2	2	4	6	2	17	15	5	9		66	152	86
Investigational Drug QA	280	280	297	295	366	371	716	476	521	606	377	456	5,041	5,978	937
SPD										3,000			3,000	2,600	(400)
License Pymt/Royalty														83	83
Other														(192)	(192)
Judgment															
Total	1,119	1,192	1,563	1,715	1,417	1,761	2,093	1,862	1,669	5,486	1,658	1,524	23,059	22,897	(162)

COMMENTS:
A) Unfavorable PARD variance due to effort on impurity and color issues, as well as an apparent underestimate of the required effort in the April Update.

CONFIDENTIAL
ABBT0578007

28-Jan-02
PAGE 8:19

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
TSP PEPTIDE ABT510

	MONTHLY RESULTS												YTD Total	YTD Approved APU	Yr
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	71	140	252	161	70	98	71	83	63	61	101	76	1,247	1,704	457
Drug Safety	24	43	46	8	39	45	25	8	21	31	43	33	366	1,045	679
Metabolism	2	10	2	6	14	20	(21)	2	2	6	1	1	45	164	119
Toxicology/Pathology	5	1	3	9	2	3	15	41	...	(41)
Comparative Medicine
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin	10	9	(1)
Medical Services	1	1	1	...	1	1	1	1	1	1
Phase-IV
Phase-I Center	10	14	28	20	29	30	19	...	29	13	9	8	209	205	(4)
Clinical
ACPRU - Direct
Development Operations	7	6	6	9	3	14	11	13	8	10	9	5	101	88	(13)
Data Management	2	7	5	19	21	12	7	6	11	18	1	6	115	120	5
Biostatistics	1	5	11	(18)
Research Information Ctr
Information Mgmt & Tech
International Manpower	115	116	49	78	77	77	110	111	111	111	44	111	1,110	1,444	334
Grants - Domestic	2	3	2	1	...	2	1	...	12	9	(3)
R&D Project Services	1	1	1	...	2	3	3	2	2	15	29	14
International Directors	61	58	56	108	25	36	20	140	63	72	58	92	789	756	(33)
Venture Management	55	158	133	136	98	204	94	114	73	118	117	94	1,394	1,139	(255)
PARD	1	3	...	6	4	25	5	3	3	10	3	1	64	74	10
Regulatory Affairs	9	3	14	6	13	4	5	6	1	5	5	2	73	56	(17)
Research QA
Re-org	2	2	1	3	3	3	3	4	12	...	1	4	38	52	14
Investigational Drug QA	187	185	203	205	259	253	307	300	391	258	247	369	3,164	3,383	219
SPD
License Pymt/Royalty	...	1	1	(2)	(3)
Other
Judgment
Total	548	751	805	771	672	816	661	795	807	719	643	806	8,794	10,275	1,481

COMMENTS

- A) Increase due to higher manufacturing costs at Cook.
B) Delay in ROSS submissions and 5 month extension of end date for M01-302.

CONFIDENTIAL
ABBT0578008

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
MMPI DEVELOPMENT ABT770/ABT518

28-Jan-02
PAGE B-18

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	YTD Total	YTD Approved APL	Val
Discovery	22	77	107	151	76	163	10	13	16	10	3	...	648	948	300
Drug Safety	77	95	99	50	47	34	45	6	4	5	15	21	498	480	(18)
Metabolism	117	164	122	139	83	23	(5)	(2)	1	5	12	2	661	713	52
Toxicology/Pathology	28	29	21	15	4	97	111	14
Comparative Medicine	17	24	12	21	1	(75)
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin	1	1	1	1	1	1	1	1	...	1	10	9	(1)
Medical Services	50	(50)
Phase-IV
Phase-I Center	1	3	5	3	3	1	1	...	2	2	1	1	23	119	96
Clinical
ACPRU - Direct
Development Operations	4	4	9	12	11	8	2	4	1	3	2	1	61	56	(5)
Data Management	1	2	8	2	4	8	1	2	1	29	47	18
Biostatistics	2	3	3	3	...	(11)
Research Information Ctr
Information Mgmt & Tech	16	1	2	2	2	...	6	1	(7)	23	23	...
International Manpower	64	64	64	64	64	64	64	(248)	200	200	...
Grants - Domestic
R&D Project Services	...	2	4	3	2	2	1	5	2	3	2	1	25	27	2
International Directors	70	66	65	123	27	42	23	160	72	82	66	106	902	805	(97)
Venture Management	42	54	75	30	40	41	22	18	19	2	2	4	349	349	0
PARD	5	6	6	2	1	12	1	2	2	3	2	2	44	72	28
Regulatory Affairs	13	3	15	8	10	5	...	4	5	9	5	2	79	70	(9)
Research QA
Re-org	1	5	3	4	...	4	1	...	1	...	19	23	4
Investigational Drug QA	28	...	1	29	...	(29)
SPO
License Pym/Royalty	363	363
Other
Judgment
Total	481	603	621	682	326	321	176	(39)	120	153	111	142	3,697	4,414	717

Program Discontinued

COMMENTS

CONFIDENTIAL
ABBT0578009

28-Jan-02
PAGE B-13

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
CCM ABT594

	MONTHLY RESULTS												YTD Approved APU	YTD Total	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	5	10	5	11	4	4	8	22	1	1	1	..	72	71	(1)
Drug Safety	21	47	65	68	41	31	14	13	1	6	11	2	320	549	229
Metabolism	87	128	159	96	(24)	63	11	31	31	15	26	22	645	694	49
Toxicology/Pathology	2	1	1	4	30	26
Comparative Medicine
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin	1	1	1	..	1	1	1	..	2	2	10	9	(1)
Medical Services
Phase-IV
Phase-I Center	16	13	34	18	21	48	12	..	17	4	..	1	184	349	165
Clinical	207	207
ACPRU - Direct
Development Operations	19	30	56	24	7	3	4	3	2	1	149	243	94
Data Management	25	31	43	37	51	36	11	11	5	11	3	8	272	129	(143)
Biostatistics	2	3	7	1	5	(18)	124	124
Research Information Ctr
Information Mgmt & Tech	4	1	5	9	4
International Manpower	100	100	100	..
Grants - Domestic	..	1	1	3	2	1	..	39	39
R&D Project Services
International Directors	655	339	357	911	(565)	329	320	381	340	303	304	494	4,168	3,655	(513)
Venture Management	169	193	213	151	146	204	78	88	51	32	10	21	1,356	1,048	(308)
PARD	1	1	2	2	4	35	10	4	3	4	2	6	74	132	58
Regulatory Affairs	14	19	16	10	19	12	6	19	5	3	4	2	129	81	(48)
Research QA
Re-org	2	..	1	1	..	1	..	(1)	4	75	71
Investigational Drug QA	28	47	31	36	127	36	31	(70)	31	31	328	357	29
SPD
License Pymt/Royalty	1	141	140
Other	134	134
Judgment
Total	1,123	817	988	1,377	(259)	788	603	609	491	310	393	581	7,821	8,210	389

COMMENTS

A) Unfavorable variance due to milestone budgeting. The Plan is for 6 months of work, while the system projects it over 12 months. Venture is currently reviewing the Phase II results to determine what further funding may be required. Currently, the venture is at a "go" "no-go" decision. If a "no-go" decision is granted, the venture has identified approx. \$1.5MM in expenses that would not be incurred. If a "go" decision is granted approx. \$9MM would be required to fund the project for the rest of the year.

CONFIDENTIAL
ABBT0578010

28-Jan-02
PAGE 8-17

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
ENDOTHELIN ABT627

	MONTHLY RESULTS												YTD Total	YTD Approved APL	YTD Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	7	13	23	9	14	3	2	4	32	49	41	26	223	160	(63)
Drug Safety															
Metabolism	31	51	24	37	46	19	47	56	21	18	27	43	420	991	571
Toxicology/Pathology		3			3	4	3			5		3	21	349	328
Comparative Medicine	3												3	26	23
Strategic and Exploratory															
Medical Affairs															
Outcomes Res/Admin	11	35	30	26	38	6	22	25	28	14	16	53	304	259	(45)
Medical Services	16	17	16	16	16	16	17	16	16	16	16	17	195	178	(17)
Phase-IV												183	183		(183)
Phase-I Center	20	32	27	12	30	47	30	(14)	56	62	(14)	12	300	579	279
Clinical											6		6	696	690
ACPRU - Direct															
Development Operations															
Data Management	56	51	68	48	55	37	34	33	31	53	28	51	545	1,596	1,051
Biostatistics	79	92	80	109	67	68	60	74	56	55	62	64	866	743	(123)
Research Information Cir	5	7	11	4	5	(32)									
Information Mgmt & Tech															
International Manpower	22	12	15	17	15	17	3	3	(6)				98	170	72
Grants - Domestic	1,035	1,035	1,035	1,035	776	1,018	1,033	1,944	1,943	1,943	1,719	2,855	17,371	18,044	673
R&D Project Services	13	7	9	12		10	7	3	4	5	2	(72)		22	22
International Directors	10	11	32	28	29	23	23	42	25	28	22	11	284	154	(130)
Venture Management	548	506	504	950	216	1,413	712	(249)	571	648	459	713	6,991	6,596	(395)
PARD	217	342	429	253	538	553	311	413	378	365	385	955	5,139	3,562	(1,577)
Regulatory Affairs	17	13	13	25	16	49	14	22	14	24	21	18	246	415	169
Research QA	31	14	15	29	27	12	44	8	11	5	27	4	227	428	201
Re-org															
Investigational Drug QA	15	11	24	14	22	16	19	16	9	19	13	18	196	262	66
SPD	41	41	41	40	(146)	41	41	40	226	41	43	40	489	683	194
License Pym/Royalty															
Other														(40)	(40)
Judgment															
Total	2,177	2,293	2,396	2,664	1,767	3,320	2,422	2,436	3,415	3,350	2,873	4,994	34,107	35,874	1,767

COMMENTS

- A) Increase in PARD due to last minute charges from Cook.
B) Accrual for M00-244 delayed 1 month/1 month delay in ROSS submission M01-304, offset by accelerated spending
C) M01-283 Qtc study on hold

CONFIDENTIAL
ABBT0578011

28-Jan-02
PAGE A-38

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DISCOVERY PROJECT EXPENSE REPORT
ERECTILE DYSFUNCTION

	MONTHLY RESULTS												YTD Total	YTD Approved APU	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery Administrative Overhead	65	65	65	65	65	64	65	65	65	65	65	65	779	779	
Discovery Functional	185	199	179	182	188	187	249	251	230	225	253	234	2,562	2,220	(342)
Discovery Svc Prib/Solid-Internal	154	379	344	366	348	468	271	117	91	129	99	80	2,846	1,672	(1,174)
Discovery Service Solid-External	339	578	523	548	536	655	520	368	321	354	352	314	5,408	3,892	(1,516)
Total Discovery (less overhead)															
Drug Safety	14	21	52	72	46	49	26	29	24	34	27	22	416	304	(112)
Metabolism	2	9	12	20	43	23	4	19	8	18	11	94	263	2	(261)
Toxicology/Pathology	50	23	73	64	48	49	54	47	38	46	45	48	585	934	349
Comparative Medicine															
Strategic and Exploratory															
Medical Affairs															
Outcomes Res/Admin															
Medical Services															
Phase-IV															
Phase-I Center															
Clinical															
ACPRU - Direct															
Development Operations															
Data Management					2			2					4		(4)
Biostatistics				2		1	(3)								
Research Information Ctr															
Information Mgmt & Tech															
International Manpower															
Grants - Domestic															
R&D Project Services															
International Directors															
Venture Management					1	1							3	11	8
PARD									2	3			6		(6)
Regulatory Affairs															
Research QA															
Investigational Drug QA															
SPD															
Genet Credit															
Other															
Judgment															
Total	471	696	725	771	741	842	667	530	458	520	500	543	7,464	5,922	(1,542)

COMMENTS

CONFIDENTIAL
ABBT0578012

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
DOPAMINE

28-Jan-02
PAGE B-4

	MONTHLY RESULTS												YTD Total	YTD Approved APU	Variance
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	83	29	3	72	187	...	(187)
Drug Safety
Metabolism
Toxicology/Pathology
Comparative Medicine
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin
Medical Services
Phase-IV
Phase-I Center
Clinical
ACPRU - Direct
Development Operations
Data Management
Biostatistics
Research Information Ctr
Information Mgmt & Tech
International Manpower
Grants - Domestic
R&D Project Services
International Directors
Venture Management
PARD
Regulatory Affairs
Research QA
Re-org
Investigational Drug QA
SPD
License Pymt/Royalty
Other
Judgment
Total	106	118	143	261	628	...	(628)

COMMENTS

CONFIDENTIAL
ABBT0578013

28-Jan-02
PAGE B-20

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
EISAI ABT-751

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	YTD Total	YTD Approved APU	Var
Discovery	22	24	22	11	8	21	4	31	19	25	7	1	195	193	(2)
Drug Safety															
Metabolism	4	1	2	32	2	4	13	40	32	30	40	45	245	694	449
Toxicology/Pathology	2	6	24	57	17	23	18	8	17	6	5	1	184	202	18
Comparative Medicine	1		6	3							1		11	103	92
Strategic and Exploratory															
Medical Affairs															
Outcomes Res/Admin															
Medical Services		2	1		1	1	1	1	1		1	1	10	9	(1)
Phase-IV															
Phase-I Center															
Clinical	1	2	2	4	2	2	1		7	2	2	15	40	118	78
ACPRU - Direct															
Development Operations															
Data Management			1	2	2	1	4	10	8	5	8	11	52	73	21
Biostatistics	1		1			1	1	2		1	1	3	11	81	70
Research Information Cur						(1)									
Information Mgmt & Tech															
International Manpower	4										(1)		4	8	4
Grants - Domestic										112	112	325	549	945	396
R&D Project Services		2	2	3		2	2	1		1		(13)			
International Directors															
Venture Management	200	190	187	353	80	121	66	461	208	234	188	305	2,593	2,577	(16)
PAPD	139	191	242	127	85	93	52	117	110	136	139	152	1,583	1,231	(352)
Regulatory Affairs		1		4	3	7	2	3	1	2	3		26	73	47
Research QA			2	4	2	3	4	2			2	1	20	48	28
Re-org															
Investigational Drug QA		4	11	7	4			4	1	5			36	153	117
SPD	76	84	76	75	75	75	105	75	75	75	75	78	944	1,172	228
License Pymt/Royalty															
Other															
Judgment															
Total	450	507	579	683	281	353	274	755	479	634	583	925	6,503	7,681	1,178

COMMENTS

A) Delay in ROSS submission M00-231 & M01-303

CONFIDENTIAL
ABBT0578014

28-Jan-02
PAGE B-8

PHARMACEUTICAL PRODUCTS R&D
GLOBAL DELIVERY PROJECT EXPENSE REPORT
KETOLIDE ABT773

	MONTHLY RESULTS												YTD Total	YTD Approved APL	Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	185	219	269	210	234	296	210	271	214	284	258	84	2,734	2,419	(315)
Drug Safety															
Metabolism	45	76	105	94	97	103	42	67	98	157	130	140	1,154	1,006	(148)
Toxicology/Pathology	9	43	46	93	174	24	16	23	20	7	11	4	470	674	204
Comparative Medicine	48	51	56	21	12	...	5	15	13	27	15	23	286	46	(240)
Strategic and Exploratory
Medical Affairs
Outcomes Res/Admin	...	2	2	1	26	7	3	6	8	2	8	12	77	100	23
Medical Services	70	69	70	69	70	70	70	69	69	70	70	69	835	696	(139)
Phase-IV
Phase-I Center
Clinical	55	102	63	97	72	69	39	21	358	112	(192)	35	831	957	126
ACPRU - Direct	155	264	108	258	...	190	260	102	1,337	1,040	(297)
Development Operations
Data Management	51	92	154	159	208	206	162	207	123	167	191	154	1,874	3,033	1,159
Biostatistics	65	66	89	93	103	94	78	87	89	74	106	75	1,019	1,252	233
Research Information Cir	33	35	51	57	30	(206)
Information Mgmt & Tech
International Manpower	172	151	146	200	230	159	279	129	167	...	(575)	...	1,058	979	(79)
Grants - Domestic	5,541	5,541	5,432	5,606	5,608	5,605	200	(23)	162	2,401	2,414	7,710	46,197	47,031	834
R&D Project Services	7	6	7	6	...	14	5	13	8	8	9	239	322	142	(180)
International Directors	74	67	97	77	68	87	40	53	61	45	55	50	774	456	(318)
Venture Management	619	588	661	1,072	(292)	537	620	348	483	500	598	375	6,109	5,310	(799)
PARC	343	459	643	765	575	544	477	523	257	543	1,231	998	7,358	4,899	(2,459)
Regulatory Affairs	4	18	15	8	13	262	41	58	35	20	43	29	546	450	(96)
Research QA	28	23	76	63	36	89	63	85	40	20	28	30	581	446	(135)
Re-org
Investigational Drug QA	17	33	26	28	17	17	6	12	6	14	20	15	211	417	206
SPD	908	564	2,581	134	(1,912)	555	1,939	113	602	601	464	464	7,013	13,770	6,757
License Pymt/Royalty
Other
Judgment	...	2	2	(519)	(521)
Total	8,429	8,471	10,697	8,853	5,369	8,532	4,295	2,335	2,813	5,557	5,148	10,289	80,788	85,136	4,348

A) Unfavorable variance due to omission of a dog study in the April Update by Comparative Medicine.

B) Decrease in Clinical Grant expense reflects increase in duration of Phase III studies.

C) Favorable SPD variance reflects delay in receipt of bulk drug.

COMMENTS

CONFIDENTIAL
ABBT0578015

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 18, 2008.

Date: February 18, 2008.

/s/ Eric J. Lorenzini

Eric J. Lorenzini (*pro hac vice*)